november/december 2019 volume 15, issue 3 Advancing Biomedical Science, Education, and Health Care

Yale School of Medicine prepares to welcome its 19th dean Yale College alumna Nancy medicine and fellowship in clinical Brown has been chair of pharmacology at Vanderbilt, she joined the faculty there in 1992. medicine at Vanderbilt The path to leadership that Brown followed at Vanderbilt reflects Nancy J. Brown, MD, has been her passions for pursuing research appointed the next dean of Yale and nurturing the next generation School of Medicine (YSM), effec- of physician-scientists. She was chief tive February 1, 2020. of the Division of Clinical Pharma- Brown, who is in line to be the cology, which is part of both a basic 19th dean of the medical school science department (pharmacology) and first woman to hold the post, and a clinical department (medicine). joins Yale from Vanderbilt Uni- She served as associate dean for versity School of Medicine, where clinical and translational scientist she is Hugh J. Morgan Professor development, establishing the Elliot and chair of the Department of Newman Society to support the devel- Medicine. A 1981 alumna of Yale opment of physician-scientists, before College, where she majored in becoming chair of medicine in 2010. robert a. lisak molecular biophysics and biochem- She also co-founded the Vanderbilt Under her stewardship, Vander- Nancy Brown takes office as dean on February 1. istry, Brown earned her medical Master of Science in Clinical Investi- bilt’s Department of Medicine, Her early priorities include improving the work climate at the School of Medicine, exploring new degree at Harvard University. After gation program to train investigators which today has more than 900 opportunities to develop physician-scientists, and completing her residency in internal in patient-oriented research. faculty members and // Dean (page 11) supporting Yale’s strategic plan for science. Gift launches Yale autoimmunity center A new pathology chair is named, will The Colton Center’s mission arrive in March is to identify and nurture Chen Liu, MD, PhD, research leading to cures will become chair of the Department What do type 1 diabetes, rheumatoid of Pathology at Yale arthritis, systemic lupus erythemato- School of Medicine sus (SLE), multiple sclerosis, inflam- and chief of Pathol- matory bowel disease, and celiac ogy at Yale New Ha- disease have in common? As different ven Hospital, effective as they are in clinical presentation, Chen Liu March 1, 2020. they share an important characteris- Liu comes to Yale from Rutgers tic. Each is an autoimmune disease. University, where since 2015 he has More than 80 different autoim- been professor and chair of pathology, mune diseases occur as a result of immunology, and laboratory medicine the immune system attacking the at New Jersey Medical School and body’s own organs, tissues, and cells, Robert Wood Johnson (RWJ) Medi- causing inflammation and cell death. cal School and chair of the Center for Some 23.5 million individuals are robert a. lisak Dermatology at RWJ Medical School. affected in the U.S., and the diseases’ Joseph Craft is the inaugural director of the Colton Center for Autoimmunity at Yale, established through He is also chief of service at University a gift from philanthropists Judith and Stewart Colton. Diseases that affect some 23.5 million Americans are prevalence continues to rise. Scien- the focus of the center, which will nurture innovative research with a goal of finding safe, effective treat- Hospital in Newark and RWJ Univer- tists lack a clear understanding of ments and preventives. sity Hospital in New Brunswick and the causes of autoimmune disorders, chief of the Division of Oncological Pa- limiting their ability to develop safe, philanthropists Judith and Stewart Paul B. Beeson Professor of Medicine thology at the Rutgers Cancer Institute effective treatments and preventives. Colton have donated a major gift and professor of immunobiology, of New Jersey. With a keen interest in autoim- to establish the Colton Center for the center will focus on nurturing After obtaining his medical mune disease and a shared vi- Autoimmunity at Yale. Under the the development of new diagnostics, degree at Tong Liao Medical College sion of finding new therapies, direction of Joseph E. Craft, MD, therapies, // Autoimmune (page 10) at Inner Mongolia // Chair (page 5)

Non-Profit Org. INSIDE THIS ISSUE 1 Church St., Suite 300, New Haven, CT 06510-3330 U. S. Postage www.medicineatyale.org 2 Lifelines PAID Karen Santucci, MD, believes emergency New Haven, CT department care can change the trajectories Permit No. 526 of young lives, and has made it her calling. 3 Putting genomics to novel uses The medical school and Yale New Haven Health have launched Generations, an ambitious DNA sequencing project. 11 The value of palliative care Jennifer Kapo, MD, becomes the first holder of an endowed professorship that honors palliative care and her practice of it. FOLLOW & SHARE twitter.com/YaleMed facebook.com/YaleMed instagram.com/YaleMed lifelines University opens state-of-the-art science building

Karen Santucci has been On October 29, a caring clinician at times when her patients may need the University her most. Hers is the first dedicated the face many see when they arrive at Yale New Haven new Yale Science Health pediatric emergency Building (YSB) departments in New Haven and Greenwich. She also has on the footprint been a leading administrator of the former at the School of Medicine and the health system. J.W. Gibbs Anna Marie Pyle Laboratory. YSB, which will serve as a cen- tral hub for interdisciplinary col- laboration on Science Hill, is de- signed to bring natural light into lab spaces, and contains common areas intended to bring researchers Karen Santucci together as they walk through the robert a. lisak building. Its approximately 550 occupants include members of the departments of molecular, cel- Care when a child has a sudden need lular, and developmental biology; and of molecular biophysics and A career of treating young Santucci always had an interest in of her success—and the emergency biochemistry. patients and seeing that pediatrics, but ultimately chose pediatric department’s achievements— to her col- It includes a cryo-electron emergency rooms run well emergency medicine because she knew leagues. “I work with absolute giants,” microscopy facility as well as life- that was the only way she could leave she says. “They’re amazing people, and I microscopy, chemical-synthesis, Karen Santucci, MD, professor of pediat- some of her work “at the office.” would do just about anything for them.” and insectary and aquatics cores; rics (emergency medicine) and of emer- “I knew I had to control when I had The same goes for her patients. Pedi- a quantitative biology center, and gency medicine, usually has two things in patient exposure because I get very atric emergency medicine presents its physics laboratories. her purse: dollar store items, and snacks. invested in them,” she says. “Having own special sets of challenges, she says, Both carry important significance to her trusted colleagues to whom I can pass due to how young incoming patients are “This building is completely work in the pediatric department at Yale the baton at the end of a shift was a way and, oftentimes, their fear of doctors. unique among modern science New Haven Children’s Hospital, where to have everything in the hospital, but The right knee of Santucci’s scrubs is buildings because of the breadth she performs several roles including have a family too.” often worn thin from the amount of time of scientific endeavor that it is section chief of emergency medicine and Santucci came to Yale in 1999. That she spends kneeling next to beds, com- designed to accommodate,” said interim section chief of pediatric oncology same year she helped design and launch a forting both patients and their families. Anna Marie Pyle, PhD, Sterling and hematology. She also is vice chair for pediatric emergency medicine fellowship But she also finds treating children to be Professor of Molecular, Cellular, clinical affairs in the Department of Pedi- program, which now receives more than a more hopeful endeavor than treating and Developmental Biology, and atrics at the School of Medicine. 100 applicants a year for two available some adults. chair of the YSB Building Com- The snacks she keeps with her are positions. And that was just the beginning “One of the beautiful things about pedi- mittee. “Most important, when for meetings or shifts in the emergency of her influence in the department. atric emergency medicine is that we’re the future inevitably comes, the department, to keep everyone energized. Santucci has been section chief of getting to these children early enough The dollar store items she uses as props pediatric emergency medicine since that we might actually be able to change labs inside YSB can be completely and prizes during her Friday rounds, which 2010, and until recently served as medical a trajectory,” she says. “There’s a very dif- dismantled to do new kinds of she calls TGIIFF—Team Gathering Innova- director of emergency pediatrics, before ferent illness set on the adult side.” science that we don’t even envi- tion, Information, Facts, and Fun. Providing transitioning to vice chair of clinical When she is not in the emergency sion today.” for her team and her patients is a corner- affairs. Two and a half years ago she was department, Santucci is running between “In 100 years, when people stone of Santucci’s professional career. also asked to start a pediatric emergency her offices, juggling her administra- look back to this moment, they Born near New York City, Santucci was medicine program at Greenwich Hos- tive roles. It has been a little tricky, she will see that this was when we the first in her family to go to college and pital, which is part of Yale New Haven admits, since she now spends half her put a stake in the ground for the first to pursue medicine. She credits Health. It went live in November 2018. time in Greenwich. She is putting in our aspirations in research and watching her firefighter father as early Santucci is supported by 12 pediatric 80-90 hour weeks. education,” added President Peter exposure to the world of emergency care. emergency physicians from Yale New Luckily her family, including her Salovey, PhD ’86. Santucci received her BS in biology Haven Children’s Hospital, and says the husband and two children aged 23 and from the College of Mount Saint Vincent. program is performing extremely well. 18, are very understanding. “My kids are But she almost did not go to medical “Watching other community hospi- very supportive of the fact that when I’m school—her college advisor urged her tals, we recognized over the years that not able to be at home, it’s because I’m Managing Editor Robert Forman not to apply, saying that she wouldn’t get strength in recruiting and retention cor- off taking care of someone else’s child Contributors Jenny Blair, Riley Davis, Pamela in. She accepted a teaching fellowship relates with having the academic affili- who needs help,” she says. Hartley, Bill Hathaway, Ziba Kashef, Mary Ann Littell, at New York University instead. Halfway ation with Yale,” she says. “It’s really a So far, her two hospital schedules have Jill Max, Karen N. Peart, Kathleen Frey Raven, Jim Shelton, Ashley P. Taylor, Kevin Wang, William Weir, through the year she realized that landmark event to have 13 of us from Yale rarely conflicted, save one evening when and Sarah C.P. Williams medicine still called to her, and decided to working at Greenwich and representing Santucci was called by the emergency Design Jennifer Stockwell apply to New York-based medical schools. Yale School of Medicine and Yale New department at Greenwich when she was Web Coordinator/Proofreader Cheryl Violante She was accepted to the State Univer- Haven Children’s Hospital.” on shift at Yale New Haven Children’s Medicine@Yale is published four times each year by: sity of New York Downstate College of Santucci’s efforts in Greenwich were Hospital. When she finally arrived in Yale School of Medicine, Office of Communications 1 Church Street, Suite 300, New Haven, CT 06510-3330 Medicine, where she also completed her recognized this past May, when she was Greenwich, a bit flustered but only a few Telephone: (203) 785-5824 Fax: (203) 785-4327 residency before moving to Providence, honored at Greenwich Hospital’s annual minutes late, she says the staff there Email [email protected] Rhode Island, to complete a fellowship at Under the Stars event. But in keeping had only one question for her: “Does this Website medicineatyale.org Hasbro Children’s Hospital. with her low-key style, she credits most mean you didn’t bring snacks?” Copyright ©2019 by Yale University. All rights reserved. If you have a change of address or do not wish to receive future issues of Medicine@Yale, please write to us at the above address or via email at [email protected]. Billingsley is named Smilow Cancer Hospital’s chief medical officer Postal permit held by Yale University, 155 Whitney Avenue, New Haven, CT 06520 Kevin G. Billingsley, MD, has been Knight Cancer In- and optimize multidisciplinary named chief medical officer at stitute among other team structure, assist with facili- Robert J. Alpern, MD Smilow Cancer Hospital and pro- senior positions. ties/space planning, and support Dean and Ensign Professor of Medicine Roopashree Narasimhaiah fessor of surgery at Yale School of At Smilow and the research mission. Associate Vice President for Development Medicine, effective January 2020. Yale New Haven Billingsley earned his medical & Alumni Affairs (203) 436-8504 Billingsley comes to Yale from Health, he will degree at Johns Hopkins School of Mary Hu Associate Dean for Communications and Oregon Health and Sciences oversee quality Medicine and trained in surgical on- Chief Communications Officer University (OHSU), where he has and patient-safety cology at Memorial Sloan Kettering been medical director of the OHSU Kevin Billingsley initiatives, evaluate Cancer Center. Printed on recycled paper ♻

2 www.medicineatyale.org advances DNA sequencing to guide research, care Health & Science News Headway is made on Program anticipates participation by many comprehensive heart failure and cardiomyopathy programs, averting renal cysts patients who can learn their own cancer and treats patients with cardiac amyloidosis, which occurs when deposits of an abnormal protein called amyloid take the place heart risks and help uncover broader trends of normal heart muscle and affect heart function. Jacoby, Ed- ward J. Miller, MD, PhD, associate professor of medicine and At a ceremony at Yale Center for Clinical Investigation on radiology, and Nikolaus Papoutsidakis MD, PhD, instructor September 4, Yale School of Medicine and Yale New Haven of medicine (cardiology), are also investigating how the con- Health System officially launched Generations, one of the dition progresses. They anticipate that data from Generations largest DNA sequencing projects of its kind in the United will be a foundation for that work. States. The aim is to enroll more than 100,000 patients in Jacoby notes that the condition, which disproportion- Yale researchers have discovered and near Connecticut, whose DNA will then be analyzed by ately affects African Americans, is often misdiagnosed as how the polycystin 2 (PC2) gene Yale scientists to develop useful data for predicting, prevent- hypertensive heart disease and treated as such. “The usual alters the energy status of cells when ing, and treating what may eventually be hundreds of gene- medications that are used to treat heart failure don’t actually PC2 is mutated to cause autosomal related conditions. work in cardiac amyloidosis,” he says. “Beta blockers and ACE dominant polycystic kidney disease Its architects envision Generations as a benefit to both the inhibitors can make things worse.” (ADPKD), an inherited condition with clinic and the laboratory. Its most immediate application may Jacoby expects the Generations information to be life- no cure. be for the actual volunteers who donate blood samples for enhancing, by minimizing misdiagnoses and symptoms that Barbara Ehrlich, PhD, professor analysis. If their genetic information suggests elevated risk for go untreated while steering treatment in the right direction. of pharmacology and of cellular and specific conditions related to cardiac disease or cancer—condi- “If you’re 25 years old and you go into the Generations Project molecular physiology, and colleagues tions that are considered “actionable” by the medical commu- and you find out you have the associated mutation, a couple of used high resolution microscopy as nity—health professionals at Generations will inform them. well as animal models to study the “What we can do right now is we can give back to 2% to 3% of impact of PC2 mutations on mitochon- people information that they wouldn’t otherwise know about dria, which generate cellular energy. serious life-threatening risks that they can do something about. They discovered that PC2 normally That’s revolutionary,” says Michael F. Murray, MD, professor of acts to limit the physical interac- genetics and director of clinical operations for Yale’s Center for tions between the mitochondria and Genomic Health, who is in charge of Generations. endoplasmic reticulum (ER)—another Murray was recruited to Yale after building a similar cellular organelle where proteins are program at Geisinger Health System in Danville, Pennsylva- produced and modified. When PC2 is nia. He says genomic information collected there indicating mutated, the team reported May 7 in elevated breast cancer risk was revealing. “We have very clear Science Signaling, interactions between examples of some patients who had cancer detected at a very the ER and mitochondria increase. early stage, and cured, and will never have to suffer with the This leads to more signaling on the disease. That’s life changing for them.”

surface of the mitochondria, more Changing the lives of people with conditions unrelated robert a. lisak energy production, more mitochon- to cancer or heart disease will take longer. For instance, since At the official launch of Generations on September 4, (l-r): Richard Lisitano dria, and—in response to the increased and Marna Borgstrom of Yale New Haven Health (YNHH), Dean Robert Alpern, effective therapies do not yet exist for Alzheimer’s, volunteer Keith Churchwell of YNHH, Michael Murray, and Brian Smith. Generations is energy—proliferation of kidney cells donors will get no information on their risk for that. “We can’t one of the largest DNA sequencing projects of its kind in the United States and to form harmful cysts. Blocking the currently intervene on Alzheimer’s,” says Murray. “There is no hopes to enroll more than 100,000 volunteer participants. excess energy production in mito- treatment or prevention for it.” Generations will only inform chondria, Ehrlich and her colleagues volunteer donors of their genetic risk when research makes a things are going to happen. One is you’re going to know, and found, stopped the production of new condition treatable. For this year’s donors, that could mean we’ll keep close tabs. If something starts to come up, we can cells in cysts. being notified years from now. “There are 20,000 genes,” begin treatment right away. Second, there’s a fair chance that says Murray. We’re giving back information on between 10 one of your parents will have the gene, and, in fact, have some New clues to heart and 100 genes. That leaves more than 99% that we’re not clinical problems related to it that they may not previously have attending to because we don’t know what to do yet about been aware of. And they’ll be able to get treatment.” muscle thickening conditions they might cause.” “I think genetic discovery within the next five to 10 years Hypertrophic cardiomyopathy (HCM), Murray says Yale’s location will produce a scientifically will become as routine as a blood test at birth” Giraldez says. in which the heart muscle grows too meaningful cohort of participants. “Connecticut is the fourth He predicts that childhood maladies could also become a thick and contracts too hard, is often closest match to the U.S. population in the census data for eth- prime focus. “That might be ADHD, autism, or other genetic caused by mutations in the cardiac form nicity and race,” he notes. “This is a great place to pilot genomic conditions, which present more suddenly and can have ir- of the muscle protein myosin. But Stuart medicine.” That, he says, will allow Generations to make great reversible effects if not treated promptly. It is hard for a family Campbell, PhD, associate professor of strides in a field where existing data tend to be skewed. “The to learn that, but it’s also hard when you have to jump from biomedical engineering and of cellular datasets are very biased toward Europeans. We know that doctor to doctor for a diagnosis or when some kids might not and molecular physiology, suspected could mean missed opportunities when you try to apply that be easily diagnosed.” that changes to the extracellular matrix information to somebody from a different part of the world.” Genomic analysis may also help clinicians customize (ECM), the scaffolding that supports As patterns related to specific diseases and demographic medication regimens. Rebecca Pulk, PharmD, clinical coordi- cells, might contribute to HCM. groups are found, Yale practitioners will then put their find- nator for pharmacogenomics at Yale New Haven Health, looks To test that hypothesis, Campbell ings into practice for patients of Yale Medicine and the Yale forward to providing actionable results that can improve care. and his team took diseased heart New Haven Health System. “We learn from every patient “Genes linked to metabolic and transporter pathways have muscle from pigs that serve as animal whom we treat within the health center,” says Brian R. Smith, known population based variations that affect medications,” models of HCM, chemically removed MD, professor and chair of laboratory medicine, deputy dean she explains. “An example finding would be the DPYD gene the cells, and seeded the decellular- for scientific affairs, co-director of the Yale Center for Clinical which codes for the enzyme dihydropyrimidine dehydro- ized and diseased matrix—as well as a Investigation, and co-principal investigator of the Yale Clini- genase. Fluorouracil, a chemotherapy used in GI and breast control matrix from healthy pigs—with cal and Translational Science Award Program. “As a conse- malignancies, relies entirely on this enzyme for clearance. healthy human heart cells generated in quence of that, we do a better job with the next patient we Patients receiving fluorouracil who genetically do not produce cell culture. treat, and on and on.” functional versions of this enzyme are at risk of life-threatening As Campbell and his team reported One exciting thing to learn will be why certain people bone marrow toxicity. Through identification of those at risk July 24 in JACC: Basic to Translational who carry a disease-causing gene mutation do not become ill. for toxicity, lower doses or alternative treatments can be used.” Science, the diseased matrix was stiffer “I think a big question is why some people with the same mu- Generations builds on a heritage of genetics-related firsts than its healthy counterpart, and the tation get a disease and others don’t,” says Antonio Giraldez, at Yale School of Medicine. Robert J. Alpern, MD, dean and tissue that resulted from the seeding of PhD, chair and Fergus F. Wallace Professor of Genetics, who Ensign Professor of Medicine, notes that “Yale actually had healthy cells onto diseased matrix ex- says evaluating healthy people will be as important as analyz- the foresight decades and decades ago to form the first de- hibited the contractile defects of HCM. ing those who have symptoms. “If you only study the people partment of genetics in the country.” Now, he says, “we have The stiff diseased matrix may have who have the disease, you cannot discover what protects you.” the ability to tie it all together, and really participate in what is triggered the hypercontractility in Clinical trials and other patient studies will also be more going to be a revolution in health care, and we’re really look- the healthy heart cells, the authors efficient to construct because potential participants are -al ing forward to being a part of it.” suggest. Future work will investigate ready in the database. In the words of Antonio Giraldez, who led the recruit- how the ECM affects contractility, Daniel L. Jacoby, MD, associate professor of internal ment of Michael Murray to Yale, “When we look back at this Campbell says. medicine (cardiovascular medicine) and director of the in 10 or 20 years, it will have been transformative.”

Medicine@Yale November/December 2019 3 out & about

May 6 At a launch event for May 8 Professor emeritus and former deputy dean Robert H. Gifford, MD, (left), Elevate, a new policy labora- traveled to Fort Myers and Wellington, Fla., for Gatherings with Alumni. Among tory housed in the Yale Child those present was Ellis Webster, MD ’91, an otolaryngologist in Loxahatchee. Gif- Study Center in collaboration ford made an appeal with Women’s Health Research for alumni support for at Yale, Chelsea Clinton, vice financial aid to help chair of the Clinton Foundation, move the medical participated in a panel discus- school closer to its sion with Megan Smith, DrPH, ambitious goal of elimi- (left), associate professor of nating all need-based psychiatry and in the Yale Child student loans and Study Center; and Kelvin Chan, replacing them

PhD, (right), director of the fitzsousa michael with scholarships. Robin Hood Foundation’s Fund

for Early Learning. harold shapiro

1.

1.

2. 3.

Yale May 20 2. School of

Medicine’s (3) harold shapiro Commence- May 31—June 1 Alumni returned to campus for Reunion, which featured the ment keynote dean’s State of the School address, awards, and presentations from students speaker, former and faculty. 1. Members of the Class of 1999 caught up with each other over an U.S. Surgeon alfresco dinner. 2. John Kirk, MD ’94 (right), and Cynthia Parenteau, channeled General Vivek some Yale spirit with pompoms and a cardboard cutout of Handsome Dan. Murthy, MD ’03, 3. A panel of alumni shared their experiences in personal career advancement. MBA ’03, urged graduates to nurture deep June 6 The Iva Dostanic, interpersonal MD, PhD, Physician-Scientist connections to Trainee Award, given in counterbalance memory of its exception- an “epidemic” (2) decarlo anthony ally talented namesake who of loneliness and isolation in society, especially among physicians. 1. From left, was a trainee at the medical Murthy; Robert J. Alpern, MD, dean and Ensign Professor of Medicine; and Class school, was awarded to Shelli of 2019 graduate Michael Boyle, MD. 2. More Class of 2019 graduates sharing Farhadian, MD, PhD, assistant infectious smiles, from left, Raysa Cabrejo, MD; Herbert Castillo Valladares, MD; professor of medicine (infec- and Lawrence Chan, MD. tious diseases). The honor for anthony decarlo anthony Farhadian included presenting at the Department of Internal Medicine’s Medical Grand Rounds. From left, Pre- drag and Dragana Dostanic, parents of Iva; Farhadian; Vincent Quagliarello, MD, professor of medicine (infectious diseases) and clinical chief of infectious diseases, and Peter S. Aronson, MD, C.N.H. Long Professor of Medicine (nephrology) and of cellular and molecular physiology.

July 31 At the Carl Fellow- ship Conference, students and teachers from Native American tribes visited the Yale Child Study Center as fellows during a two-week education immer- sion program that supports child development and mental health in Native American communi-

anthony decarlo anthony ties. The fellows were supported anthony decarlo anthony May 23 At the Marguerite Rush Lerner Creative Writing and Art Contest, by the Charles W. Carl Jr., MD sponsored by the Program for Humanities in Medicine, medical students submit- Training Fellowship Fund. From left, Mark Beitel, PhD, assistant clinical professor ted a total of 85 submissions of poetry, prose, and visual art. Natnael (Natty) of psychiatry; Charles W. Carl, Jr., MD ’63, a psychiatrist in private practice in Mas- Doilicho (left), and David Nam, both Class of 2022, pose with Waypoint, a sachusetts, who started the fund; Christopher Cutter, PhD, assistant professor in photograph they arranged together. the Child Study Center; and Jordan Barlow, a grant writer for the Modoc tribe.

4 www.medicineatyale.org advances A gift funds innovative Lyme research Health & Science News Instead of targeting the Lyme A new approach to bacterium, the goal is to block insulin regulation the mechanism of infection

The Steven & Alexandra Cohen Foun- dation has pledged $1.8 million over three years to fund Lyme and tickborne disease research by Erol Fikrig, MD, Waldemar Von Zedtwitz Professor of Medicine (Infectious Diseases) and When blood sugar rises, beta cells in professor of epidemiology (microbial the pancreas release insulin, causing diseases) and of microbial pathogen- cells to take in more glucose and keep- esis. The gift will fund Fikrig’s novel ing blood sugar levels steady. Problems approach to developing an anti-tick with this feedback mechanism can vaccine. Instead of trying to target result in such metabolic disorders as the Lyme disease-causing bacterium, harold shapiro diabetes and hypoglycemia. Borrelia burgdorferi, as other approaches their opening. In studies of guinea With support from the Steven & Alexandra Cohen Scientists already knew that ATP, Foundation, Erol Fikrig is taking a novel approach have, Fikrig plans to target the Ixodes pigs, Fikrig’s lab has already found to preventing ticks from spreading Lyme disease. cellular fuel produced through glucose tick that spreads disease, essentially that the animals can resist tick bites breakdown, triggers insulin release, and by stymieing the tick’s ability to take a based on immunity to proteins that the Approximately 300,000 people since the oxidative phosphorylation blood meal. tick produces in the first 24 hours of contract Lyme disease in the U.S. each step (OxPhos) in glucose metabolism “The Steven & Alexandra Co- attachment. Such immunity not only year, and the numbers are thought to produces significant ATP, OxPhos was hen Foundation has provided good prevents the tick from feeding, but also be increasing. Most live in the North- thought to regulate insulin secretion. resources, so we can go at it full steam impairs infection with Borrelia. east and upper Midwest, a distribution However, research led by Richard G. ahead,” says Fikrig, an expert in dis- That discovery lines up with likely to expand with climate change. Kibbey, MD, PhD, associate professor eases spread by insects and ticks who another line of evidence from people The disease can cause short-term of medicine, indicates that another also is chief of the Infectious Diseases living in areas endemic to Lyme flulike symptoms and rash; over the product of glucose metabolism, mito- Section of the Department of Inter- disease: Those who have been bitten long term, it can cause facial paralysis; chondrial GTP (mtGTP), does the same nal Medicine and a Howard Hughes often by ticks that don’t carry Borrelia arthritis; inflammation of the heart, thing—independent of OxPhos. Medical Institute investigator. seem to acquire some protection from brain, or spinal cord; and fatigue, As reported July 16 in Cell Reports, “Let’s say you’re drinking a drink the parasites over time. “Many will among other problems. Symptoms can when Kibbey’s team overexpressed out of a straw, and the straw gets tell you ticks don’t bite them as well persist long after antibiotic treatment. the protein that makes mtGTP in beta clogged,” Fikrig explains. “That’s what as they used to,” Fikrig says. These A previous human Lyme vaccine cells, insulin levels increased in vitro. we’re trying to work on—blocking [the people’s bodies may be creating anti- called LYMERix that targeted Borrelia In mice overexpressing the mtGTP tick] from feeding.” bodies to the ticks’ salivary proteins. burgdorferi sold poorly and was with- progenitor protein, insulin levels also When ticks first bite, they inject Fikrig’s lab is currently examining drawn from the market in 2002. rose, and blood sugar levels dropped. proteins that prepare a favorable thousands of tick-saliva proteins to find Since its inception in 2001, the mtGTP also appeared to protect beta environment for a meal—the event the most promising targets. Once they Stamford, Connecticut-based Steven cells from metabolic stress. Kibbey during which various pathogens can be have cloned 15 to 20, the team will & Alexandra Cohen Foundation has says these results point to the mtGTP transmitted to the host. These proteins begin testing them in animal models. funded projects in multiple areas, in- pathway as a promising new target for block blood clotting, inflammation, “This is an innovative approach cluding Lyme and tickborne disease, diabetes drugs. and immune responses. Fikrig’s vaccine to stopping Lyme infection, which underserved communities, children’s would prevent them from functioning, remains very difficult both to diagnose health and education, the arts, and Drug may have an encouraging the tick to give up, drop off, accurately and to treat effectively,” sustainability. Inspired by Alexan- ovarian cancer role and look for another mammal to bite. says Alexandra Cohen, who launched dra Cohen’s personal struggle with Unlike with a mosquito, which can the Cohen Lyme & Tickborne Disease Lyme disease, the foundation has In a recent clinical trial, combining inject pathogens immediately after bit- Initiative in 2015. “Lyme is one of the committed over $60 million to more the rarely used cancer drug cediranib ing, it takes a tick up to 48 hours after fastest-growing diseases in the United than two dozen projects addressing with the more mainstream drug ol- biting before introducing Borrelia into States and is terribly debilitating for far prevention, diagnosis, treatment, apraib treated recurrent ovarian cancer the host. That delay gives researchers too many people who are infected.” education, and ecology. better than olaparib alone—a surpris- ing finding. Now, Yale researchers have discovered exactly how cediranib // Chair (page 1) University of Nation- discovery. That’s the part that really for Medical Microbiology, and the works and why it might be useful in ality in China, Liu did postgraduate excited me.” Center for the Studies of Stillbirth and combination with other treatments. training at Peking Union Medical Col- As a well-recognized gastrointes- Early Infant Death. During the past The team, led by Peter M. Glazer, lege. He went on to receive his PhD tinal and liver pathologist, he provides four years, the department doubled the MD, PhD, chair and Robert E. Hunter in pathology from the University of expert consultations for physicians and number of faculty, and significantly in- Professor of Therapeutic Radiology, Pennsylvania School of Medicine. He patients. He has several patents and creased clinical revenue, NIH funding, and professor of genetics, studied completed his residency in anatomical pending applications for his research, and academic productivity. the drug using isolated human cancer and clinical pathology at Hahnemann which focuses on the epigenetic driv- Liu is a lifetime fellow of the Col- cells as well as human tumors in mice. University Hospital, an oncological ers that cause liver cancer in a virally lege of American Pathologists and a They found that cediranib, in addition pathology fellowship at MD Anderson infected or alcohol-exposed liver. This two-time recipient of the Technology to its known role in blocking blood Cancer Hospital, and postdoctoral work has contributed to the understand- Innovator Award from the University vessel formation, also stops a cellular training at Scripps Clinic. ing of liver cancer carcinogenesis and of Florida. He has received awards program called homology-directed Before joining Rutgers, Liu was biomarker discovery for early diagnosis for teaching and mentoring from the DNA repair. Tumor cells rely on this professor and vice chair of pathology, and therapeutic targets. He also is using University of Florida, Howard Hughes program to repair their DNA when immunology, and laboratory medicine immunotherapy to treat liver cancer, Medical Institute, and NIH. it is damaged by such treatments as at the University of Florida, where he specifically engineering T cells and nat- At Yale, he plans to continue to pur- radiation or chemotherapy. also held an endowed chair in gastro- ural killer (NK) cells to boost their anti- sue innovative research while educating While other drugs block molecules intestinal and liver research. In his role cancer activity, which will soon be tested the next generation of investigators and involved in homology-directed DNA as chair at Yale, he will succeed Jon S. in a clinical trial. His research programs physicians. His goal is to provide ex- repair, cediranib works at an earlier Morrow, PhD, MD, chair and Ray- have been continuously funded by the ceptional patient-centered care and cap- stage, affecting the expression of mond Yesner Professor of Pathology. National Institutes of Health (NIH) and ture new opportunities in the changing genes involved in the process, the re- Liu is motivated by a desire to other agencies since 2003. health care landscape. “Yale’s Depart- searchers reported May 15 in Science bring the most innovative research to At Rutgers, Liu led the integration of ment of Pathology has a great reputa- Translational Medicine. medicine. He says he chose to special- pathology and dermatology programs, tion and a group of very distinguished Combining cediranib with DNA- ize in pathology “because it’s really a expanded dermatology clinics, and world-class faculty and staff,” Liu says. damaging agents could deliver a bridge department. You can do trans- increased the size of the dermatology “With that foundation, I think we can double blow to cancer cells, the new formational research, bringing discov- residency program. He also established further elevate its distinction nationally results suggest. ery to the bedside, and the bedside to the Immunology Division, the Center and internationally.”

Medicine@Yale November/December 2019 5 Grants and contracts awarded Genetics of Alcohol Dependence in African Aging Lung Cell Atlas (NALCA), 4 years, Americans: Recruitment, 5 years, $1,952,611 $2,661,807 • Naftali Kaminski, Ivan Rosas, Wendy Gilbert, NIH, RNA Pseudouridylation NIH, Epithelial Protective Effects of Thyroid to Yale School of Medicine During Flavivirus Infection, 2 years, $502,500 Hormone Signaling in Fibrosis, 5 years, Thomas Gill, Heather Allore, Thilinie Banda- $3,227,151 • Insoo Kang, NIH, Aging and IL-7 ranayake, Xi Chen, Guido Falcone, Shelli Far- Mediated CD8+ T Cell Survival, 4.8 years, July 2018–March 2019 hadian, Terri Fried, John Hwa, Janice Hwang, $1,842,500 • Alanna Kaplan, NIH, Tumor- Manisha Juthani-Mehta, Insoo Kang, Morgan selective Inhibition of DNA Repair using pHLIP, Federal Levine, Becca Levy, Brienne Miner, Joan 3 years, $108,072 • Rachel Kaspari, NIH, Novel Clara Abraham, NIH, Functional Outcomes of Dementia and Decision-Making for Older Monin, Margaret Pisani, Vincent Quagli- Insights into the Role of the Hypothalamic- Inflammatory Bowel Disease Associated Vari- Adults without Surrogates, 4.8 years, arello, Maor Sauler, Albert Shaw, Hongyu Pituitary-Thyroid Axis in Skeletal Muscle Adap- ants, 4 years, $2,294,633 • Fuad Abujarad, NIH, $1,178,480 • Daniel Colón-Ramos, NIH, Power- Zhao, NIH, Claude D. Pepper Older Americans tive Thermogenesis, 2 years, $72,875 • Dionna Feasibility of Virtual cOaching in making ing the Brain: The Cell Biology of Neuroener- Independence Center at Yale, 5 years, Kasper, NIH, Defining miR-223-dependent Informed Choices on Elder Mistreatment Self- getics, 4.8 years, $5,862,500 • Elizabeth $6,356,005 • Antonio Giraldez, NIH, Func- Mechanisms Regulating Hematopoietic Stem Disclosure (VOICES), 3.6 years, $1,494,862 Connors, NIH, Selecting and Testing Implemen- tional Analysis of Autism Risk Genes During Cell Production from Endothelium, 2 years, Serap Aksoy, NIH, Molecular Aspects of tation Strategies to Advance Measurement- Neural Development Using Single Cell Seq., $205,432 • Trace Kershaw, NIH, Understand- Tsetse and Trypanosome Transmission, based Care in School Mental Health, 4 years, 4.9 years, $2,924,347 • Michael Girardi, ing Relapse and the Impact of Social Networks 5 years, $4,103,771 • Christopher Anderson, $638,820 • Joseph Contessa, NIH, Regulation Marcus Bosenberg, David Hafler, Ruth and Geographic Settings During Treatment for NIH, Human Tissue Engineered Pulsatile Con- of N-linked Glycosylation in Mammalian Cells, Halaban, Harriet Kluger, Shuangge Ma, David Alcohol-Related Problems, 4.9 years, $3,485,717 duits Using Engineered Heart Tissue of 2 years, $658,654 • Philip Corlett, NIH, Neuro- Stern, Qin Yan, NIH, Yale SPORE in Skin Cancer, Kenneth Kidd, Curt Scharfe, National Institute Defined Composition and Fiber Orientation, computational Mechanisms of Auditory Hallu- 5 years, $4,824,996 • Emily Goldberg, NIH, of Justice, Better Forensic Markers: Microhap- 3 years, $133,572 • Amy Arnsten, NIH, Preclini- cinations, 2 years, $404,250 • Kelly Cosgrove, Impact of Ketone Bodies on Age-Related lotypes and Ancestry SNPs, 1.5 years, cal Assessment of GCPII Inhibitors for Cogni- Sherry McKee, Marina Picciotto, NIH, Sex- Inflammation and Healthspan Extension, $1,083,499 • Daniel Kim, NIH, Exploring the tion and Tau Pathology, 4.8 years, $3,755,936 Appropriate Treatment Development for 2 years, $202,998 • Elena Gracheva, NSF, Innate Sensors Underlying Cancer Immunosur- Paul Aronson, DHHS, Development and Pilot Alcohol Use Disorders, 1.9 years, $450,722 Molecular Basis of Cold Tolerance, 1.1 years, veillance, 3 years, $109,608 • Megan King, NIH, Trial of a Web-Based Tool to Facilitate Shared Kelly Cosgrove, Robert Malison, NIH, Neuro- $300,001 • Daniel Greif, DoD, Cell Type- Remodeling of the Structure and Function of Decision-Making with Parents of Febrile immune Disruption in Opioid Use Disorder, Specific KLF4 Regulation of Lung Fibrosis, 3 years, the Nuclear Lamina by LINC Complex-Dependent Infants, 3 years, $460,170 • Peter Aronson, 2 years, $209,375 • Chris Cotsapas, NIH, $1,162,741; NIH, Vascular Disease Pathogenesis: Tension, 4.2 years, $1,340,000 • Megan King, Lloyd Cantley, Joseph Craft, Shuta Ishibe, Shared Genetics and Risk Factors Between Epi- The Interface of Smooth Muscle and Immune Simon Mochrie, Corey O’Hern, NSF, EFRI CEE: Shrikant Mane, Dennis Moledina, Patricia lepsy and Psychiatric Disease, 5 years, Cells, 4 years, $2,288,212 • Daniel Greif, Carlos Sculpting the Genome by Design: Epigenetic Preisig, Stefan Somlo, Francis Wilson, NIH, $2,452,828 • Joseph Craft, NIH, Follicular Fernandez-Hernando, NIH, Aging and Clonal- and Chromatin Looping Inputs to Measure and George M. O’Brien Kidney Center at Yale, Helper T Cell Function in Autoimmunity, ity in Atherosclerosis, 1.9 years, $460,625 Manipulate Chromatin Organization and 5 years, $3,982,508 • Peter Aronson, NIH, 4 years, $1,326,600; NIH, Pathogenic Lympho- Carlos Grilo, NIH, Cognitive-Behavioral and Dynamics, 5.1 years, $1,899,968 • Steven Klein- Roles of SLC26 Transporters in Urinary Oxalate cytes in Lupus Nephritis, 2 years, $445,978 Pharmacologic Treatment of Binge Eating Dis- stein, NIH, Computational Tools for the Analy- Excretion and Kidney Disease, 4.8 years, Larry Davidson, SAMHSA, Mental Health New order, 4.9 years, $3,572,024 • Eduardo Groisman, sis of High-Throughput Immunoglobulin $2,774,337 • Craig Bailey, Marc Brackett, England Technology Transfer Center (MH- NIH, Control of Carbohydrate Utilization in the Sequencing Experiments, 4 years, $1,673,023 Institute of Education Sciences (IES)/U.S. NETT), 5 years, $4,538,806 • Maggie Davis, Prominent Gut Bacterium Bacteroides The- John Krystal, NIH, The 4th International Con- Department of Education, Promoting School NIH, Dysregulation in Mglur5 as a Marker of taiotaomicron, 3.7 years, $1,328,478 • Murat ference on Applications of Neuroimaging to Readiness through Emotional Intelligence: BPD and Suicide Related Endophenotypes, Gunel, Angeliki Louvi, Ketu Mishra, NIH, Func- Alcoholism (ICANA-4), 1 year, $25,000 • Priti An Efficacy Trial of Preschool RULER, 5 years, 5 years, $983,483 • J. Lucian Davis, NIH, tional Validation of Intracranial Aneurysm Risk Kumar, NIH, T Cell-targeted Lentiviral Vectors $3,243,018 • Stephen Baldassarri, NIH, Under- Human-centered Design and Communities of Genes, 5 years, $3,014,549 • Jiankan Guo, with Cas9/RNP for the In Vivo Gene Therapy standing Factors that Influence Electronic Cig- Practice to Improve Delivery of Home-based Lloyd Cantley, NIH, Generation of Macrophage of HIVAIDS, 4.9 years, $3,669,702 • Priti Kumar, arette Nicotine Delivery Through PET Imaging TB Contact Investigation in Uganda, 5 years, Activation State-Specific Genetic Tools by a Karen Anderson, NIH, Long-acting Combina- of Beta-2 Nicotinic Acetylcholine Receptors, $3,642,351 • Catherine Deatherage, NIH, Synthetic Biology Approach, 2 years, $460,625 tion Antiretroviral Therapy for HIV-AIDS, 5 years, $983,335 • Daniel Barson, NIH, Devel- Reconstitution of Retromer Dependent Cargo Junjie Guo, NIH, Molecular and Cellular Deter- 2 years, $598,150 • Alex Kwan, NIH, Frontal opmental Participation of VIP Interneurons in Sorting, 2 years, $122,784 • Jonathan Demb, minants of RNA Repeat-associated Properties, Cholinergic Signals During Value-Based Cortical Dynamics, 2 years, $58,548 • Jean- NIH, Functional Circuitry of Long-Range Con- 4.7 years, $2,512,500 • Romi Gupta, NIH, Per- Decision-Making, 1.9 years, $460,625 • Themis Denis Beaudoin, NIH, Analysis of the Molecu- nections in the Retina, 3.8 years, $2,012,746 sonalized Therapy for p16-Deficient Mela- Kyriakides, NIH, Bulk Metallic Glass Nano- lar Machinery Regulating Gene Expression Andrew Dewan, Suzanne Leal, NIH, Detecting noma, 2 years, $83,750 • Stephanie Halene, moulding for Glucose Sensors, 3.9 years, during Vertebrate Development, 2 years, Pleiotropic Effects Through Integration of DoD, Mechanisms of Bone Marrow Failure and $1,658,091 • TuKiet Lam, NIH, High Resolution $230,700 • Amy Bei, NIH, Employing Genetic Omics Data, 4 years, $2,833,492 • Sabrina Leukemia Progression in Primary Human Tandem Mass Spectrometer to Meet Growing and Genomic Surveillance to Reveal Mecha- Diano, NIH, Intercellular Mechanisms of Fanconi Anemia Stem Cells in a Novel FA PDX Demand for Proteomics at Yale, 1 year, nisms of Malaria Parasite Persistence, 3 years, Microglia Activation in Diet-induced Obesity, Model, 2 years, $662,124 • Ali Hamodi, NIH, $572,240 • Michael Leapman, NIH, Under- $414,315 • Chyrell Bellamy, NIH, Peer Wellness 4.8 years, $3,385,902 • Katie Digianantonio, Development of Cortical Circuits Using Multi- standing the Adoption and Impact of New Risk Enhancement for Patients with Serious Mental NIH, Probing the Mechanism by which TRIM5 scale Optical Imaging in Awake Mice, 3 years, Assessment Technologies in Prostate Cancer Illness and High Medical Costs, 1.7 years, Proteins Sense HIV Capsid Assemblies, $190,477 • Michelle Hampson, Ilan Harpaz- Care, 4 years, $1,017,668 • Eli Lebowitz, Dylan $661,500 • Anton Bennett, NIH, Institutional 10 months, $59,038 • Gail D’Onofrio, Rotem, NIH, Neurofeedback of Amygdala Gee, NIH, Brain Response Associated with National Research Service Award, 5 years, SAMHSA, The Yale MAT Training Program: Activity for PTSD, 1.9 years, $1,154,287 Parent-Based Treatment for Childhood $1,699,865 • Joerg Bewersdorf, NIH, An Inte- Expanding Treatment Access, 3 years, William Hancock-Cerutti, NIH, Investigating Anxiety Disorders, 2 years, $1,516,350 • Francis grated Imaging System for High-throughput $449,746 • Gail D’Onofrio, Patrick O’Connor, the Lipid Transport Properties of VPS13C at Lee, NIH, Non-hormonal Function of Locally Nanoscopy of the 4D Nucleome, 2 years, NIH, Yale Drug use, Addiction and HIV Membrane Contact Sites in Relation to Parkin- Delivered PTH for Rescue of Impaired Fracture $660,001 • Shivani Bhatt, NIH, Investigating Research Scholars (DAHRS), 5 years, son’s Disease Pathogenesis, 2 years, $58,608 Healing, 5 years, $2,404,806 • Daeyeol Lee, the Role of Glucocorticoid Function in PTSD, $2,606,682 • Vincent Duong, NIH, Tenofovir Michael Hanna, NIH, Investigation of ER- Weiji Ma, NIH, CRCNS: Neural Basis of Plan- 3 years, $127,068 • Michael Bond, NIH, Devel- Inhibition of Human Mitochondrial Poly- endosome Contact Site Dysfunction Underlying ning, 11 months, $523,874 • Katie Leiby, NIH, opment of a Tumor-Specific PROTAC, 4 years, merase Primpol and Mechanisms of Antiviral Pathomechanism of Hereditary Spastic Para- Regeneration of Distal Lung Epithelium via $119,276 • Alfred Bothwell, NIH, Thrombocyte Therapy-driven Nephrotoxicity, 3 years, plegia, 3 years, $150,851 • Nicola Hawley, NIH, Epithelial-Mesenchymal Co-Culture and Mod- Regulation of Anti-Parasite Immunity, 5 years, $93,858 • Stephanie Eisenbarth, James Development of Samoan-specific Fetal Growth ulation of Wnt Signaling, 3 years, $106,779 $2,093,750 • Martina Brueckner, NIH, Cilia in Surprenant, NIH, Immune Mechanisms Regu- References and an Assessment of Their Diag- Ifat Levy, NIH, Decision Making and Learning Heart Development and Disease, 7 years, lating Allergy, 5 years, $3,069,880 • Irina nostic Ability, 1.9 years, $183,324 • Robert Under Uncertainty in Aging, 1.9 years, $5,212,390 • Gabriela Buccini, NIH, Pathways Esterlis, NIH, In Vivo Imaging of a Neural Heimer, DHHS, Outcomes from the Continua- $757,408; NSF, Decision Making Under Uncer- to Scale Up Integrated Early Childhood Devel- Marker of Suicidal Behavior in Bipolar Disor- tion of Methadone Treatment for Opioid Use tainty Across the Lifespan: Cognitive, Motiva- opment Programs, 2 years, $250,818 • William der, 5 years, $3,935,570 • Guido Falcone, NIH, Disorder in the CT Corrections System, 1 year, tional and Neural Bases, 3 years, $801,045 Cafferty, NIH, Temporal Profiling of Cortico- Genetic Analyses of Radiological Severity, $444,471 • Kevan Herold, NIH, Mechanisms of Chiang-Shan Li, NIH, A Cholinergic Mecha- spinal Motor Neurons Reveals Novel Thera- Short-Term Functional Outcome and Long- Autoimmune Diabetes in Patients Treated nism of Impulsive Response in Young Adult peutic Targets for Spinal Cord Injury, 2 years, Term Health Status in Spontaneous Intrace- with Immune Checkpoint Inhibitors, 2 years, Cigarette Smokers, 2 years, $400,725 • Zeyan $460,625 • Christina Camell, NIH, Macro- rebral Hemorrhage, 5.7 years, $1,187,214 $251,250 • Erica Herzog, DoD, Cell Type- Liew, NIH, Neurodevelopmental Effects of Per- phage Inflammasome Activation and the Shelli Farhadian, NIH, Understanding the Specific KLF4 Regulation of Lung Fibrosis, 3 years, fluorinated Chemicals, 2.9 years, $822,632 Mechanism of Lipolysis Resistance in Aged Cellular Basis for Persistent Immune Activa- $1,019,978 • Ansel Hillmer, NIH, Imaging the Young Lim, NIH, Exploring the Mechanism of Adipose, 11 months, $101,499 • Lloyd Cantley, tion in the Central Nervous System During Opioid Response to Cannabis Smoking, 1 year, Genetic Reversion in Ichthyosis with Confetti, Peter Aronson, NIH, Methods in Nephrologic Virologically Suppressed HIV, 3.9 years, $251,250 • Michael Hines, NIH, Computer 1 year, $29,244 • Janghoo Lim, NIH, Regulation Research, 5 years, $2,414,761 • Richard Carson, $770,281 • Shawn Ferguson, NIH, Axonal Methods for Physiological Problems, 3.8 years, of Inhibitory Interneuron Development, NIH, A Program for Innovative PET Radioligand Endo-lysosome Transport Mechanisms that $1,465,624 • Joy Hirsch, NIH, Mechanisms of 1.9 years, $460,625 • Kasia Lipska, Victor Development and Application: A Translational Regulate APP Processing, 4.7 years, Dynamic Neural Coupling during Face-to-Face Montori, NIH, QBSafe: A Novel Approach to Toolbox for Treatments for Mental Health, $2,093,750; NIH, Molecular Mechanisms that Expressions of Emotion, 4.8 years, $2,033,148 Care for Older, Complex Adults with Type 2 3 years, $3,536,103 • Sreeganga Chandra, NIH, Match Lysosome Function to Cellular Ya-Chi Ho, NIH, Role of Clonal Expansion in Diabetes, 1.9 years, $466,802 • Chi Liu, Michael Role of Glucosylsphingosine in Parkinson Demand, 4.1 years, $1,373,500 • Erol Fikrig, HIV-1 Persistence, 5 years, $2,894,524 • Tamas Casey, NIH, Personalized Task-Based Respira- Disease and Dementia with Lewy Bodies, Albert Shaw, NIH, Circadian Rhythms and Horvath, Xiao-Bing Gao, NIH, Hypocretinergic tory Motion Correction for Low-Dose PET/CT, 4.8 years, $2,480,685 • Sandy Chang, DoD, Innate Immune Response in Aging, 5 years, Control of Cocaine Abuse, 4.8 years, $2,416,018 5 years, $3,220,474 • Carrie Lucas, NIH, Novel Role of BRIT1 in Suppressing Genomic Instabil- $2,416,813 • Clare Flannery, NIH, Obesity- Yingqun Huang, NIH, H19 Long Noncoding Signaling Roles for the DNA Damage Response ity and Triple Negative Breast Carcinogenesis, driven Endometrial Hyperplasia in Postmeno- RNA in Hepatic Gluconeogenesis Regulation, Kinase CHK1 in TCR/ITAM Signaling, 5 years, 3 years, $1,256,250 • Herta Chao, NIH, Neuro- pausal Women: Synergistic Role for Insulin 3 years, $1,243,776 • Henry Huang, NIH, PET $2,340,351 • Alexandra MacColl Garfinkel, cognitive Changes from Long-Term Androgen and Estrone, 5 years, $2,336,929 • James Radiotracers to Image the Enzyme 11beta- NIH, Mitochondrial Energetics Define Cardiac Deprivation Therapy in Prostate Cancer Freeman, NIH, Safety and Effectiveness of hydroxysteroid Dehydrogenase-1 (11beta- Patterning and Early Development, 3 years, Patients, 5 years, $1,956,331 • Marek Chawarski, Left Atrial Appendage Closure in Atrial Fibril- HSD1), 1.9 years, $1,631,066 • Shuta Ishibe, NIH, $107,764 • Robert Malison, NIH, Clinical NIH, Implementation of Seek, Test, Treat & lation (SAFELY-AF), 11 months, $656,551 Yale Summer Undergraduate Medical Research Neuroscience Research Training in Psychiatry, Retain Strategies among People Who Inject Charles Fuchs, Brinda Emu, Lisa Fucito, Ann (Yale SUMR), 5.2 years, $604,658 • Yasuko 5 years, $1,326,745; NIH, Imaging Synaptic Drugs in Malaysia, 4.9 years, $2,798,783 Haberman, Beth Jones, Shrikant Mane, Iwakiri, DoD, Hemodynamic Changes and Pan- Density in the Opiate Addicted Brain using 11C Sidi Chen, NIH, (PQ4) Novel Tools For In Vivo Ravinder Nath, David Rimm, Amer Zeidan, creatitis, 1.5 years, $335,000 • Elizabeth Jonas, UCB J PET, 2 years, $460,625 • Mark Mamula, Study of Genetic Interactions in Cancer NIH, Cancer Center Support Grant, 5 years, NIH, Mitochondrial Ion Channels in Hypoxic Kevan Herold, NIH, Autoimmunity to Protein Progression, 5 years, $2,865,835; NIH, High- $23,291,480 • Charles Fuchs, NIH, Yale Neurons, 3 years, $1,115,480 • Elizabeth Jonas, Modifications in Checkpoint Inhibitor Induced throughput In Vivo Genetics for Immuno- Cancer Center, NCTN LAPS, 6 years, Rachel Perry, NIH, Regulation of Tumor and Spontaneous T1D, 2 years, $167,500 therapy Target Discovery, 4.9 years, $2,512,500 $4,397,760 • Jorge Galán, NIH, Predoctoral Growth and Metabolism by Hyperinsulinemia Kathleen Martin, Patrick Gallagher, NIH, Keith Choate, NIH, Mechanisms of Revertant Training Program in Microbial Pathogenesis, and Inflammation, 4 years, $689,305 • Arie Coordinated Regulation of Vascular Smooth Mosaicism in Ichthyosis with Confetti, 5 years, 5 years, $1,190,090 • Gigi Galiana, NIH, Dis- Kaffman, NIH, PU.1 as a Putative Master Regu- Muscle Phenotype by p300, CBP, and TET2, $2,483,768 • Hyung Chun, DoD, Role of Endo- tinguishing Lipid Subtypes by Amplifying lator of Neurodevelopmental Abnormalities of 3.9 years, $2,198,243 • Sherry McKee, thelial Dysfunction as a Key Pathogenic Driver Contrast from J-Coupling, 2 years, $460,625 ELS, 2 years, $557,556 • Kristopher Kahle, NIH, SAMHSA, Collaborative Care Model for Reen- of Hypertrophic Cardiomyopathy, 1.5 years, Patrick Gallagher, Peter Glazer, Mark Modulation of Choroid Plexus Immuno- tering Offenders: The Living-Free Program, $333,778; NIH, Role of Endothelial Regulation Saltzman, NIH, Nonenzymatic Gene Editing Secretory Function to Restore Cerebrospinal 5 years, $2,125,000 • Ruslan Medzhitov, NIH, of Fatty Acid Uptake in Metabolic Dysfunction, in Treatment of Heredity Spherocytosis, Fluid Homeostasis in Hydrocephalus, 4.9 years, Role of GDF15 in the Regulation of Host Toler- 4 years, $2,114,240 • Andrew Cohen, NIH, 3.8 years, $2,437,234 • Joel Gelernter, NIH, $1,832,030 • Naftali Kaminski, NIH, Normal ance to Inflammation, 5 years, $2,093,750

6 www.medicineatyale.org Wajahat Mehal, NIH, Inhibition of Sterile Health Services Research, 5 years, $1,585,341 $2,605,840 • Vasilis Vasiliou, Yong Zhu, NIH, Mednet (NSF), An Online Peer-to-Peer Inflammation by Digoxin in Alcoholic Hepatitis, Nenad Sestan, NIH, 1/2 Cell Type and Region- Summer Research Experience in Environmental Resource for Oncologists to Improve Clinical 4.8 years, $1,206,325 • Thomas Melia, Patrick Specific Regulatory Networks in Human Brain Health (SREEH), 5 years, $530,035 • Eric Trial Knowledge and Enrollment, 1 year, $47,979 Lusk, NIH, Defining the Nucleophagy Mecha- Development and Disorders, 4.7 years, Velazquez, Robert Mentz, NIH, TRANSFORM- Binod Aryal, American Diabetes Association, nism: Opening New Doors for Aging Research, $6,470,160; NIH, Technology for Functional HF CCC, 3.9 years, $6,098,320 • Terril Verplaetse, Defining the Role of Glial ANGPTL4 in Lipid 1.9 years, $459,815 • Jaimie Meyer, SAMHSA, Study of Cells and Circuits in Large Postmor- NIH, Behavioral and Neurochemical Mecha- Metabolism in the Brain and Obesity, 3 years, CHANGE: Comprehensive Housing and Addic- tem Brains Ex Vivo, 3 years, $2,801,084 nisms Underlying Stress-Precipitated Drinking, $190,114 • Andrea Asnes, State of CT Dept of tion Management Network for Greater New Juliana Shaw, NIH, Arg and Cortactin Regula- 5 years, $814,735 • Joseph Vinetz, NIH, Public Health, DPH—Child Sexual Abuse Haven, 5 years, $1,933,368 • Verica Milivojevic, tion of the Arp2/3 Complex and its Role in Addressing the Global Burden of Leptospirosis Program, 5 years, $571,171 • David Assis, PSC NIH, The Role of Neuroactive Steroids in Dendritic Spine Stability, 2 years, $76,740 in Two Endemic Countries, 1.3 years, $424,613; Partners Seeking a Cure, An Investigation of Stress, Drug Craving, and Drug Use in Cocaine Albert Shaw, NIH, Midcareer Award in Transla- NIH, Amazonian Center of Excellence in Biliary-Immune Interactions and Candidate Use Disorder, 5 years, $912,980 • Kyle Mohler, tional Immunology of Aging, 4.7 years, Malaria Research, 5.4 years, $6,154,456; NIH, Drug-Screening Using Novel Bile-Derived NIH, Investigating Mechanisms of Kinase- $937,980 • Sangini Sheth, NIH, Implementation Predicting Risk of Human Leptospiros by Envi- Organoid Technology, 2 years, $60,000 Mediated Cell Migration in Aggressive Glio- of Inpatient Postpartum Human Papillomavirus ronmental Surveillance, 1.6 years, $370,145; Marc Auerbach, Baylor College of Medicine blastoma, 3 years, $178,586 • Dennis Moledina, Immunization, 5 years, $680,328 • Cynthia Shi, NIH, Translational Research Development for (DHHS), National Emergency Medical Ser- NIH, Identification of Non-Invasive Biomarkers NIH, HIV Testing and Partner Notification Ser- Endemic Infectious Diseases of Amazonia, vices for Children (EMSC) Resource Centers and Indices for Diagnosis of Drug-Induced vices for Women in China, 2 years, $89,540 2.3 years, $669,457 • Narendra Wajapeyee, Demonstration CA, 1.5 years, $36,660 • Craig Acute Interstitial Nephritis, 4.9 years, $919,510 Gerald Shulman, NIH, Development of Con- DoD, CA170103-A Druggable Epigenetic Bailey, Tauck Family Foundation, Expanding Joan Monin, NIH, A Daily Self-Regulation Inter- trolled Release Mitochondrial Protonopohore Vulnerability Pathway in P53-Deficient Hepa- Social and Emotional Learning in Bridgeport vention for Persons with Early Stage Alzheim- (CRMP) as a Novel Treatment for Type-2 Dia- tocellular Carcinoma, 9 months, $699,999 Early Childhood Settings using RULER, er’s Disease and Related Dementias and their betes and Non-Alcoholic Steatohepatitis in Narendra Wajapeyee, Romi Gupta, NIH, A 5 years, $831,555; Hartford Foundation Spouses, 2 years, $472,585; NIH, Attachment Dysmetabolic Non-Human Primates, 5 years, Druggable Chromatin Modifier Pathway in for Public Giving, Supporting Social and Emo- Behaviors in Parent Child Dyads Coping with $2,692,184 • Frederick Sigworth, NIH, High- HCC, 9 months, $103,485 • Tong Wang, NIH, tional Learning in the Capitol Region’s Early Early Stage Alzheimer’s Disease and Related throughput Electron Cryo-microscope, Defective Flow-dependent Tubule Transport in Childhood Settings, 3 years, $299,739 Dementias, 4.8 years, $3,905,935 • Evan 1.5 years, $1,950,000 • Michael Simons, the Pathogenesis of Kidney Disease, 3.8 years, Lilanthi Balasuriya, American Psychiatric Morris, NIH, Does Dopamine Mediate Effects William Sessa, Martin Schwartz, Jiasheng $1,500,938 • Peng Wang, NIH, Mental Illness Association, American Psychiatric Associa- of Stress on Inhibitory Control and Smoking Zhang, Zhenwu Zhuang, NIH, Molecular Stigma as a Risk Factor for Substance Use tion Minority Fellowship, 2 years, $26,070 Lapse?, 4.8 years, $5,396,413 • Chima Ndumele, Mechanisms of Arterigenesis, 4.8 years, Among Adults with Depression, 5 years, Lauren Baldassarre, American Heart Associ- NIH, Leveraging Physician Networks to $9,546,298 • Rajita Sinha, NIH, Neuroactive $885,918 • Emily Wang, Cary Gross, NIH, ation, Advanced Cardiovascular Magnetic Improve Care and Outcomes for Low-Income Steroid Potentiation to Decrease Alcohol Incarceration and Cancer-Related Outcomes Resonance for Detection of Programmed Cell Populations, 3 years, $1,641,256 • Lena Nguyen, Craving, Normalize HPA Axis Function and (ICRO), 4 years, $1,788,109 • Scott Weatherbee, Death Protein-1 Deficient Myocarditis, NIH, mTORC1-dependent Translational Prevent Alcohol Relapse, 4 years, $2,762,370 NIH, Genetic Analysis of Organ Patterning 3 years, $231,000 • Susan Baserga, Breast Control in Developmental Epilepsy, 3 years, Rajita Sinha, Wendy Silverman, NIH, Prevent- Defects in Ciliopathies, 5 years, $1,955,900 Cancer Alliance, Targeting the Nucleolus $183,246 • Stefania Nicoli, NIH, PPIL4 Modula- ing Childhood Obesity Through a Mindfulness- Daniel Weinberger, Virginia Pitzer, NIH, Pre- for Breast Cancer Therapy, 1 year, $100,000 tion of Notch Links Neurovascular Malforma- based Parent Stress Intervention, 5 years, dicting and Monitoring Variations in the William Becker, University of Massachusetts tion to Brain Aneurism, 5 years, $1,832,030 $3,518,986 • Dana Small, NIH, Cognitive and Effects of Vaccines against RSV, 4.9 years, Lowell (NIH), Identifying Opioid Overdose Stefania Nicoli, Karen Hirschi, NIH, miR-223 Affective Influences on Taste Processing, $2,278,103 • Craig Wilen, NIH, Role of Virus- Predictors using EHRs, 4.7 years, $274,158 Regulates Endothelial to Hematopoietic Tran- 2 years, $1,056,748 • Marcella Smith, Peter Receptor Interactions in Determining Norovi- Choukri Ben Mamoun, University of Califor- sition, 1 year, $99,999 • Michael Nitabach, NIH, Adams, Rohan Maharaj, Cruz Nazario, rus Tropism and Pathogenesis In Vivo, 3 years, nia, Irvine (NIH), Hit-to-Lead Development of Training Program in Molecular Medicine, Maxine Nunez, NIH, Pediatric ECHORN $704,633 • Samuel Wilkinson, NIH, Effects of the Kalihinol Scaffold for Malaria Treatment, 5 years, $937,333 • Stephanie Noble, NIH, Cohort Study: Intergenerational Factors that Electroconvulsive Therapy on Suicide in Geriat- 4.9 years, $1,172,500 • Adam Berkwitt, Chil- Improving Reliability and Validity of fMRI Sta- Contribute to Cardiovascular Risk in the Eastern rics Patients with Major Depressive Disorder: dren’s Hospital of Philadelphia, Preparing tistical Methods, 11 months, $47,551 • Kevin Caribbean, 4.9 years, $3,551,824 • Mark A Nationwide Cohort Study Using Propensity for a Hybrid Trial of Pulse Oximetry De- O’Connor, NIH, Novel Approaches for Investi- Solomon, NIH, Regulation of the Anaphase- Score Matching and Instrumental Variable Analy- Implementation in Stable Infants with Bron- gating the Pathology of Myasthenia Gravis Promoting Complex, 2 years, $670,000 sis, 1.9 years, $460,625 • John Wysolmerski, chiolitis, 4 months, $2,000 • Whitney Besse, Autoantibodies, 1.9 years, $395,062 • Stephanie Stefan Somlo, NIH, Molecular Modulators of NIH, PTHrP and Cancer Cachexia, 1.9 years, PKD Foundation for Research in Polycystic O’Malley, NIH, Human Laboratory Paradigms, Polycystin Signaling, 4.9 years, $2,096,442 $405,350 • Catherine Xie, NIH, Complement Kidney Disease, Genetic Approach to Define Task Order 3, Alcohol Cue Human Laboratory Donna Spiegelman, NIH, Comprehensive Induces Inflammasome Assembly in Human Mediators of Polycystin-1 Function in Poly- Study Testing ANS-6637, 1.3 years, $424,177 Translational Science Analytics Tools for the Endothelium: Mechanisms and Consequences cystic Kidney Disease, 2 years, $160,000 • Hal Stephanie O’Malley, Suchitra Krishnan-Sarin, Global Health Agenda, 2 years, $1,362,661; NIH, for Graft Rejection, 4 years, $137,838 • Ke Xu, Blumenfeld, Tel Aviv University, Pilot Study Marina Picciotto, Jody Sindelar, NIH, Yale New Methods for the Design and Evaluation of NIH, Defining the Impact of Injection Drug Use for a Novel Paradigm to Study Conscious- Center for the Study of Tobacco Product Use Large HIV Prevention Interventions, 6 months, on Antiretroviral Therapy and HIV Treatment ness, 1 year, $35,744 • Dowin Boatright, and Addiction: Flavors, Nicotine, and Other $681,715; NIH, Statistical Methods to Account Outcomes: An (epi)genomic Approach, Northeast Group on Educational Affairs, Constituents (YCSTP), 5 years, $2,803,829 for Exposure Uncertainty in Environmental Epi- 5 years, $2,415,510 • Ke Xu, Bradley Aouizerat, Mistreatment and Microaggression against John Pachankis, Richard Branstrom, Mark demiology, 4.8 years, $3,104,464 • Sandra NIH, Feature Selection of DNA Methylation Sexual Minorities in U.S. Medical Schools, Hatzenbuehler, NIH, Biopsychosocial Mech- Springer, Ya-Chi Ho, Yuval Kluger, NIH, Evalu- Biosignatures for Neuropathy with Comorbid 1 year, $3,000 • Krysten Bold, Robert E. Leet anisms Underlying Internalizing Psychopa- ating the Role of Opioid Medication Assisted Drug Abuse in the Setting of HIV Infection, and Clara Guthrie Patterson Trust, Bank of thology in a Prospective, Population-Based Therapies in HIV-1 Persistence for Persons 4.7 years, $1,802,256 • Henry Yaggi, Nancy America, N.A., Trustee, Evaluating the Feasi- Cohort of Sexual Minority Young Adults, Living with HIV and Opioid Use Disorders, Redeker, Kevin Sheth, NIH, The Recovery in bility and Efficacy of a Real-Time Smoking 4.8 years, $3,728,011 • Noah Palm, NIH, IgA- 2.9 years, $2,240,779 • Mario Strazzabosco, Stroke Using PAP (RISE UP) Study, 4.8 years, Intervention Using Wearable Technology, Glycosylation: Mediator of Microbial Homeo- NIH, CFTR Modulates Innate Immune $3,594,039 • Xiting Yan, NIH, Deep and Inte- 2 years, $90,000 • Erin Borchardt, American stasis and Intestinal Health?, 2 years, $460,625 Response in Biliary Epithelium: Role in the grative Analysis of RNA Sequencing Data to Cancer Society, Investigating the Role of Abhijit Patel, David Zhang, NIH, Lung Cancer Pathogenesis and Treatment of Cystic-Fibrosis- Identify Pathogenesis Heterogeneity of RNA Pseudouridylation in the HCV Life Cycle, Screening via Ultrasensitive and Cost-efficient Related Liver Disease, 4.9 years, $2,793,761 Chronic Lung Disease, 2 years, $414,563 3 years, $163,500 • Angelique Bordey, Analysis of Tumor DNA Signatures in Blood, Stephen Strittmatter, NIH, Silent Allosteric Georgia Zarkada, NIH, Targeting TGFB Signal- Tuberous Sclerosis Alliance, In Utero Elec- 4.9 years, $2,569,966 • Paulina Pawlica, Ian Modulation of mGluR5 for Safe and Effective ing to Treat Ocular Neovascular Disease, troporation for TSC Preclinical Research, MacRae, NIH, Regulation of microRNA Popula- Therapy of Alzheimer’s Disease, 5 years, 2 years, $194,006 • Sheng Zhang, NIH, Imaging 2.5 years, $50,393 • Marcus Bosenberg, The tions by Oncogenic Viruses, 2 years, $180,000 $8,244,513 • Valerie Su, NIH, Phosphorylation the Hypothalamus and Motivation Deficits Salk Institute for Biological Studies (NIH), Christopher Pedigo, NIH, The Srf/Pfn1 Axis in of ICAP1 Inhibits its Nuclear Accumulation to in Cocaine Addiction, 2 years, $404,250 Mitochondrial Heterogenity in Melanoma Podocyte Biology, 1 year, $59,038 • Dana Modulate Integrin and CCM Signaling, 3 years, Z. Jimmy Zhou, NIH, Functional Dissection of Tumor and Immune Responses, 1.5 years, Peters, NIH, Development of MR-derived $103,996 • Tami Sullivan, Office of Violence New Retinal Circuits, 4 years, $2,493,312 • Yong $48,910 • Kevin Boyé, American Heart Parameters of LV Diastolic Function: Validation Against Women, Development, Implementa- Zhu, NIH, Explore piRNA as a Novel Therapeutics Association, On-demand Opening of the and Comparison to LV and LA Fibrosis, 4 years, tion and Evaluation of an Integrated, Peer-Led, for Hepatocellular Carcinoma, 2 years, $400,744 Blood-Brain Barrier through Unc5B Regula- $1,830,429 • Christopher Pittenger, Alan Group Intervention for Survivors of Domestic tion, 2 years, $104,060 • Marc Brackett, Anticevic, NIH, Brain Network Changes Violence, 3 years, $439,540 • Patrick Sung, Non-federal Dalio Foundation, Introducing the Principles Accompanying and Predicting Response to NIH, Roles of the Nucleic Acid Motor Protein Sarah Abdallah, Howard Hughes Medical and Practices of Emotional Intelligence into Pharmacotherapy in OCD, 5 years, $751,765 ZGRF1 in Chromosome Damage Repair, Institute, Uncovering Somatic Mosaic Variants Connecticut Schools, 1.2 years, $700,000 Renato Polimanti, NIH, Investigating the 5 months, $209,375 • Hemant Tagare, NIH, in Obsessive-Compulsive Disorder, 1.7 years, Dena Simmons, University of Virginia, Eval- Systems Genetics of the Patterns of Polysub- DaTscan-based Disease Progression Models $43,000 • Jean Adnopoz, Child Health & uating the Impact of RULER, a School-wide stance Abuse and Addiction, 2 years, $369,450 for Early-stage Parkinson’s Disease, 3.8 years, Development Inst. of Connecticut, CHDI Ser- Emotion-focused Intervention, on Teacher Al Powers, NIH, A Hearing Test for Hallucina- $1,405,183 • Wenwen Tang, NIH, The Role of vices FY19 Frometa, 10 months, $59,408 • Jean Well-being, Classroom Climate, and Stu- tions: Toward Development of Computational MAP3K2/3 in Modulating Neutrophil ROS Adnopoz, Karen Hanson, The Nicholson Foun- dents’ Academic and Social-emotional Skills Markers for Early Diagnosis, 5 years, $983,201 Release and its Translational Potential, dation, New Jersey Program Consultation, in Elementary School, 5 years, $845,758 Helen Pushkarskaya, Christopher Pittenger, 3.9 years, $1,675,000 • Jeffrey Testani, Veena 7 months, $21,398 • Claudio Alarcon, The V Christopher Bunick, William O. Seery Men- NIH, Evidence Accumulation in Obsessive- Rao, NIH, Urine Galectin-3 as a Biomarker of Foundation for Cancer Research, Epitranscrip- tored Research Award for Cancer Research, Compulsive Disorder During Perceptual and Cardio-renal Phenotype and Prognosis, 2 years, tomic Regulation of Cancer Metastasis, Bank of America, N.A., Trustee, Develop- Value-Based Decisions, 1.9 years, $460,625 $251,250 • Christian Tschudi, NIH, Mechanism 2 years, $200,000 • Yomi Alimi, Howard ment of the First-in-Class Anti-Cancer Valerie Reinke, John Carlson, NIH, Predoctoral of Infectivity Acquisition in African Trypano- Hughes Medical Institute, Pharmacokinetics Therapeutics Targeting Keratin Intermedi- Training Program in Genetics, 5 years, somes, 5 years, $2,311,805 • Federico Vaca, and Pharmacodynamics of a Novel Anti- ate Filaments, 2 years, $90,000 • Jian Cao, $3,306,534 • Joseph Ross, DHHS, Yale-Mayo NIH, Trajectory Outcomes of Teens that Ride renalase Monoclonal Antibody in Mice, 1 year, Melanoma Research Foundation, Targeting Clinic FDA Center of Excellence in Regulatory with Impaired Drivers & Drive Impaired, $38,000 • Heather Allore, University of Mas- KDM5 Histone Demethylases to Boost Science and Innovation (CERSI), 5 years, 5 years, $2,882,196 • Federico Vaca, Eduardo sachusetts Medical School (NIH), Advancing Immune Response In Melanoma, 2 years, $19,867,574 • James Rothman, NIH, Regulation Romano, NIH, Delaying Licensure: Latino Teens Geriatrics Infrastructure & Network Growth $100,000 • Jessica Cardin, Michael Higley, of Membrane Fusion in Exocytosis, 4 years, Riding with Impaired Drivers and Impaired (AGING) Initiative, 1.7 years, $86,967 • Frederick Simons Foundation, Identifying Convergent $2,701,702 • James Rothman, Janice Hwang, Driving, 2 years, $479,095 • Flora Vaccarino, Altice, Ukrainian Institute on Public Health Neural Circuit Impairments in Autism, NIH, Glucoregulatory Hormone Interactions in NIH, 1/3 Chromatin Regulation During Brain Policy (NIH), Integrating Treatment for Mental 3 years, $974,341 • Grace Carroll, Interna- Diabetes, 5 years, $3,300,249 • Helena Ruther- Development and in ASD, 2 years, $550,583; Disorders in Methadone Clinics in Ukraine, tional Society for Research in Human Milk ford, NIH, Addiction and Parenting: The Role NIH, Neurodevelopment of Tourette Syn- 4.9 years, $135,000; State of CT Dept of Public and Lactation, Estimating the Cost of of Aberrant Reward Process, 2 years, $251,250 drome, 4.9 years, $2,411,751 • Christopher Van Health, Comprehensive Syringe Services Implementing a Maternity Cash-Transfer Alva Sainz, NIH, Regulation of Mitochondrial Dyck, NIH, PET Imaging of SV2A and Other Program Delivery in the New Haven Area, System in Low- and Middle-Income Coun- DNA-Mediated Signaling and its Contribution Biomarkers in Alzheimer’s Disease, 5 years, 3 years, $300,000 • Anika Anam, Robert E. tries to Improve Breastfeeding Outcomes, to Cellular and Organismal Aging, 4 years, $5,540,440 • Michelle Van Name, NIH, Effect Leet and Clara Guthrie Patterson Trust, Bank 8 months, $9,816 • Jessica Cerdena, The $147,693 • Kurt Schalper, Soldano Ferrone, of Adiposity on Hepatic and Peripheral Insulin of America, N.A., Trustee, The Role of Insulin in Wenner-Gren Foundation for Anthropo- NIH, Role of the HLA Antigen Presenting Resistance and Hepatic Steatosis in Pubertal Endometrial Cancer Pathogenesis: Metabolic logical Research, Epigenetic Embodiment of Machinery (APM) in Resistance to Pd-1 Axis Adolescents with Type 1 Diabetes, 3 years, Phenotyping of Women with Endometrial Intergenerational Trauma in Latin American Blockade in Non-Small Cell Lung Cancer, $587,820 • Vasilis Vasiliou, NIH, Fourth Inter- Cancer, 2 years, $90,000 • George Anderson, Migrants in New Haven, Connecticut, 2 years, $184,465 • David Schatz, NIH, Func- national Conference on Alcohol and Cancer, Missouri Institute of Mental Health, Post- 1.2 years, $19,828 • Julius Chapiro, Lynn tion and Evolutionary Origins of the RAG Endo- 1 year, $30,000; NIH, Mouse Models and traumatic Stress Disorder and Traumatic Brain Savic, Society of Interventional Oncology nuclease, 5 years, $2,626,960 • Mark Metabolomics Tools to Investigate Alcohol Injury in Women Survivors of Intimate Partner (SIO), Molecular Imaging Biomarkers for Schlesinger, DHHS, Yale Training Program in Metabolism and Tissue Injury, 4.9 years, Violence, 4 months, $23,400 • Sanjay Aneja, the Characterization of the Tumor

Medicine@Yale November/December 2019 7 Microenvironment Effects on the Immune Fiellin, New York University School of Medi- Molecular Markers in Diamond Blackfan Genomic Studies of Tourette Disorder, Response in Liver Cancer Treated with TACE, cine (NIH), Reducing Morbidity and Mortality Anemia (DBA) Patients’ Blood Cells that 2.2 years, $122,958 • Robert King, Rutgers, 2 years, $100,000 • Sarwat Chaudhry, Mayo from Overdose, HIV, and Hepatitis C in Opioid- Predict Predisposition to Myelodysplasia/ The State University of New Jersey, Rutgers Clinic of Rochester (NIH), Unintended Pro- Using Persons, 1.8 years, $135,490 • Erol Fikrig, Acute Myeloid Leukemia (MDS/AML), 1 year, Service Agreement, 1 year, $46,056 • Brandon longed Opioid Use, 4 years, $265,015 • Arun University of Maryland (NIH), Tick Immune $100,000 • Harrison Hayward, American Kitay, Association of Directors of Medical Chavan, Cancer Research Institute, Dissecting Signaling, Microbiota, and Acquisition of Bor- Academy of Pediatrics, Immigrant Status and Student Education in Psychiatry (ADMSEP), the Evolutionary Origin of Lymphocytes, relia burgdorferi and Anaplasma phagocyto- Healthcare Resource Eligibility, 1.2 years, Proposal for a Clinical Simulation Initiative 3 years, $175,500 • Sidi Chen, Sontag Founda- philum, 5 years, $2,093,750; L2 Diagnostics $2,000 • Robert Hecht, The Alliance for Inter- (CSI) eModule on Electroconvulsive Therapy tion, Functional Interrogation of Molecular (NIH), Vaccine for Zika Virus, 11 months, national Medical Action, Nutrition Cost Effec- (ECT), 1 year, $2,500 • Steven Kleinstein, Drivers in Gliomagenesis, 4 years, $600,000 $178,212; University of Connecticut Health tiveness Analyses, 1 year, $49,100 • Ya-Chi Ho, United States-Israel Binational Science Foun- Hyung Chun, American Heart Association, Center (NIH), The Role of UBXNs in Antiviral University of Utah (NIH), Center for the Struc- dation, Jerusalem, Israel, Machine Learning Translating the Apelinergic Pathway for Immunity, 1.4 years, $71,935 • John Forrest, tural Biology of Cellular Host Elements in Approaches for Classification of Immunologi- Cardiometabolic Health, 3 years, $300,000 Medtronic, Structural Heart Disease Fellow- Egress, Trafficking, and Assembly of HIV cal Repertoires, 4 years, $81,000 • Steven Paul Cleary, University of Connecticut Health ship in Advanced Interventional Cardiology/ (Cheetah Center), 1.6 years, $75,000 • Ellen Kleinstein, Washington University in St. Louis Center (DHHS), State Innovation Model Cardiac Surgery 2018-2019, 1 year, $20,000; Hoffman, United States-Israel Binational (NIH), B Cell Receptor Repertoire Sequencing Quality Scorecard, 7 months, $67,190 • Eliza- Edwards Lifesciences, Structural Heart Science Foundation, Jerusalem, Israel, Model- Data Analysis, 9 months, $30,050 • Albert Ko, beth Connors, Jacob Tebes, University of Disease Fellowship 2018-2019, 1 year, $40,000 ing Autism Risk Genes in Zebrafish, 5 years, Emory University (NIH), Task Area B Option Maryland (SAMHSA), Supplement to the 2018 Marina Freudzon, Dermatology Foundation, $135,000 • Ellen Hoffman, Ted Abel, Simons 3.B; 17-0111, 1 year, $14,989 • Jonathan Koff, Mental Health Technology Transfer Center Understanding the Role of GILT in Malaria Foundation, Translating Drug Discovery in Jackson Laboratory (NIH), Modulation of Lung Cooperative Agreements, 1.1 years, $22,631 Transmission in Skin, 1 year, $30,000 • Gerald Zebrafish and Mouse Models of ASD Risk Immune Responses to Viral Infection, 5 years, Zack Cooper, National Institute for Health Friedland, Columbia University (NIH), Impact Genes, 3 years, $742,998 • Theodore Holford, $41,860 • Anthony Koleske, Dr. Ralph and Care Management Foundation, Why Does the of a Multimodal Intervention to Reduce Dual Regents of University of Michigan/UMH Marian Falk Medical Research Trust Bank of U.S. Overinvest in Technology? The Curious Stigma and Improve Treatment Outcomes in (NIH), Center for the Assessment of the Public America, N.A., Trustee, Modulators of TRIO Case of MRI Scanners, 2 years, $88,607 • Zafra HIV/Drug-resistant TB Co-infected Patients in Health Impact of Tobacco Regulations [(1) Guanine Nucleotide Exchange Factor Activi- Cooper, Harvard University (NIH), ESSENCE KwaZulu-Natal, South Africa, 1.8 years, $33,326 Project 1: Comparative Modeling of the Impact ties as New Therapeutics for Schizophrenia, (Enabling translation of Science to Service to Lisa Fucito, ICF Macro, Inc. (NIH), Smoke- of E-cigarettes Use on Smoking and Long-Term Autism, and Related Disorders, 1.6 years, ENhance Depression CarE), 11 months, $38,337 freeTXT eReferral Program, 1 year, $150,000 Health Outcomes, (2) Project 3: Examining the $300,000; Broad Institute, Biochemical and Peter Cresswell, Joanna Pawlak, Netherlands Patrick Gallagher, University of Pittsburgh Health and Policy Impacts of Tobacco-Related Functional characterization of Disease Associ- Organisation for Scientific Research, Unravel- (NIH), Precision Transfusion Medicine, Health Disparities Associated with Polyto- ated TRIO Variants, 1 year, $135,926 • Iryna ing the Mechanisms Behind Peptide Loading 4.9 years, $41,875 • Suhas Ganesh, Brain & bacco Use, (3) Data Analysis and Dissemina- Kolosenko, American Association of Immunol- and Editing During Antigen Cross-Presentation: Behavior Research Foundation (formerly tion Core (DAD)], 1 year, $377,041 • Henry ogists, 2019 American Association of Immu- Implications for Cancer and Viral Infections, NARSAD), The Effects of Cannabis Exposure Hsia, Plastic Surgery Foundation, iPSC Based nologists Fellowship Program for Career 2 years, $153,724 • Patrick Cudahy, American on the Adolescent Human Epigenome- a Lon- Tissue Engineered Graft for Wound Healing, Reentry, 1 year, $50,760 • Harlan Krumholz, Society of Tropical Medicine and Hygiene, Bio- gitudinal Study, 2 years, $69,824 • Gael Genet, 2 years, $49,998 • Evelyn Hsieh Donroe, Rheu- Erica Spatz, Texas A&M Engineering Experi- markers of Treatment Response and Composi- American Heart Association, EndophilinA2 matology Research Foundation, Rheumatoid ment Station (NIH), SCH: INT: A Context- tion of Multi-drug Resistant Mycobacterium Mediated VEGFR2 Endocytosis Promotes Arthritis and HIV: Establishing a Comparative aware Cuff-less Wearable Ambulatory Blood Tuberculosis Strains During Treatment, 1 year, Endothelial Cell Migration, 1 year, $56,140 Model to Understand the Role of Chronic Pressure Monitor using a Bio-Impedance $65,000 • Leslie Curry, Regents of the Univer- Nafiisha Genet, American Heart Association, Inflammation in Systemic Bone Loss, 2 years, Sensor Array, 3.8 years, $34,247 • Priti Kumar, sity of California, Linking Health Care and Connexin 43 Regulates Neurogenesis in the $100,000 • Chun Chieh Hsu, Cancer Research University of Wisconsin-Madison (NIH), Social Services for Older Adults: Area Agencies Adult Brain Subventricular Zone, 6 months, Institute, Regulation of Translation by the Exploiting Natural Post-Integration Barriers to on Aging as Key Partners, 1 year, $10,767 $27,158 • Janneane Gent, Mayo Clinic of Roch- Interferon-induced Antiviral Protein Viperin, Restrict HIV-1 Replication, 1.9 years, $197,927 William Damsky, Dermatology Foundation, ester, Olmsted County, Minnesota Air Quality 3 years, $175,500 • Jamie Hu, American Skin Gary Kupfer, University of Texas Health Elucidating and Overcoming Mechanisms Study (OMAQ), 3 years, $81,556 • Mark Gerstein, Association, Biodegradable Bioadhesive Science Center at San Antonio (NIH), Mecha- of Immunotherapy Resistance in Melanoma, University of Massachusetts, Worcester Nanoparticle (BNP) Drug Delivery in the Treat- nistic Dissection of the Falconi Anemia 2 years, $110,000; Skin Cancer Foundation, (NIH), Discovery and Validation of Neuronal ment of SCC, 1 year, $7,000 • Henry Huang Pathway of DNA Damage Response and Repair, Elucidating and Overcoming Mechanisms Enhancers Associated with the Development Huang, Centre for Addiction and Mental 1.2 years, $211,219 • Angela Lek, University of of Immunotherapy Resistance in Melanoma, of Psychiatric Disorders (Psychdac), 1.7 years, Health, Development of 18F-labeled Radioli- Massachusetts, Worcester (NIH), Novel Thera- 2 years, $50,000; • Larry Davidson, State $736,904 • Mark Gerstein, Henry Hsia, gands for Synaptic Density Imaging, 11 months, peutics for FSHD, 1.7 years, $85,134; Cure Rare of CT Dept of Mental Health and Addiction Augusta University (Formerly Georgia $247,615 • Izuchukwu Ibe, Orthopaedic Disease (formerly Terry’s Foundation for Mus- Services (SAMHSA), Promoting Integrated Regents University) (NIH), Characterization of Research & Education Foundation, Metastatic cular Dystrophy), Exploration of Upregulation Care in Connecticut (PIC-CT) 19MHA1044, Cellular and Molecular Heterogeneity in Breast Cancer and the Induction of Bone of Certain Non-muscle Full-length Dystrophin 1 year, $180,000 • Andrea Diaz Stransky Human Diabetic Foot Ulcers, 2 years, $272,097 Resorption, 1 year, $5,000 • Cristian Ionita, Isoforms, 1.5 years, $157,995 • Monkol Lek, American Academy of Child and Adolescent David Gibb, American Society of Hematology, Cure SMA, SMA Care Center Network, 1 year, Jain Foundation, Application of CRISPR Base Psychiatry, Digital Delivery of Parent Training Elucidating Mechanisms of Transfusion- $60,000 • Melinda Irwin, Breast Cancer Editing in Dysferlinopathies, 9 months, $26,670; for Disruptive Behaviors: Increasing Access induced Interferon Production and RBC Alloim- Research Foundation, Physical Activity, Diet, Neuromuscular Disease Foundation, GNE to Care (#2), 1.3 years, $15,000; American munization, 3 years, $99,999 • Thomas Gill, Weight and Breast Cancer Survivorship, 1 year, Myopathy Biobank, 1 year, $83,600 • Morgan Psychiatric Association, APA SAMHSA University of Florida (NIH), Wearable technol- $250,001 • Ryan Jensen, University of Pennsyl- Levine, University of Southern California Minority Fellowship Travel Funds, 1 year, ogy infrastructure to enhance capacity for vania, Defining the Molecular Mechanisms (NIH), Biological Underpinnings of Socioeco- $28,199 • Weilai Dong, American Heart Real-time, Online Assessment and Mobility Underlying BRCA2 and RAD51 PARP Lesion nomic Differentials In Health And Mortality, Association, Inspect Genomic Architecture Monitoring (ROAMM) of intervening health Processing, 2 years, $100,000 • Raymond 1.3 years, $13,390; Glenn Foundation for of Congenital Heart Disease by Integrating events in older adults, 2 years, $14,504 • Sarah Johnson, L2 Diagnostics (NIH), Development Medical Research, Glenn Award for Research SNVs and CNVs, 2 years, $53,688 • Rachel Goldberg, Leidos Biomedical Research (For- of a Point of Care Diagnostic Screening Test in Biological Mechanisms of Aging, 2 years, Dreyer, McGill University, Sex and Gender- mally SAIC_Frederick) (NIH), Predictors of for Kawasaki Disease, 1 year, $67,501 • Ayana $60,000 • Chiang-Shan Li, University of Texas related Differences in Access to Care for Pre- Benefit from Osimertinib with or without Bev- Jordan, American Academy of Addiction Psy- Health Science at Houston (NIH), Large-scale mature ACS: Does the Health Care System acizumab in Patients with EGFR Mutant Lung chiatry (SAMHSA), Mentoring Early Career Network Modeling for Brain Dynamics: Statis- Matter?, 1.5 years, $97,663 • Deepak D’Souza, Cancer and Brain Metastases_15X147TO2, Trainees for Culturally Informed Careers in tical Learning and Optimization, 1 year, $28,550 Wallace Research Foundation, Efficacy and 10 months, $272,128 • Pallavi Gopal, Amyo- Addiction Medicine and Addiction Psychiatry, Karel Liem, PKD Foundation for Research in Safety of DMT for Major Depression, 1 year, trophic Lateral Sclerosis Association (ALS 2 years, $239,347 • Roger Jou, Abha Gupta, Polycystic Kidney Disease, Role of Interstitial $213,930 • Nan Du, American Academy of Association), Effect of Ataxin-2 Intermediate Simons Foundation, 2019 Simons Foundation Cells Renal Cystogenesis, 2 years, $160,000 Pediatrics, Healthy Child Curriculum for Length Polyglutamine Expansion on TDP-43 Powering Autism Research for Knowledge Renelle Lim, The Tumori Foundation, Under- Refugee Families, 1 year, $2,000 • Kathleen RNP Granule Dynamics, 2 years, $200,000 (SPARK) Clinical Site Network—Yale Univer- pinnings of Response to Immunotherapy in Duffany, Southern Connecticut State Elena Gracheva, Richard & Susan Smith Family sity, 3 years, $600,000 • Kellie Jurado, Charles Uveal Melanoma, 1.6 years, $95,560 • Erika University (DHHS), Racial and Ethnic Foundation, Newton, MA, Regulation of Fluid H. Revson Foundation, Leveraging Native Linnander, Gavi The Vaccine Alliance, Imple- Approaches to Community Health (REACH), and Ionic Balance Under Extreme Physiological Immune Functions: Antibody Access to the mentation of an EPI Management Training 5 years, $129,825 • James Duncan, Pamela States in a Mammalian Hibernator, 2 years, Central Nervous System, 11 months, $100,256 Programme—Francophone Africa COHORT 2, Ventola, University of California, Los Angeles $300,000 • Valentina Greco, Leo Foundation, Inamul Kabir, American Heart Association, 1 year, $586,119 • Alicia Little, Robert E. Leet (NIH), Parsing ASD Heterogeneity: Neuro- The 2019 Gordon Research Conference on Integrin-CD36 Axis in Smooth Muscle Cell Fate and Clara Guthrie Patterson Trust, Bank of endophenotypes of Social Attention and Epithelial Differentiation and Keratinization and Clonality in Atherosclerosis, 2 years, America, N.A., Trustee, Role of T Follicular Sensory Responsivity, 1.6 years, $179,130 (GRC-EDK), 1 year, $22,384 • Carlos Grilo, $104,060 • Amanda Kallen, Washington Uni- Helper (Tfh) Cells in Chronic Cutaneous Lupus James Duncan, Denis Sukhodolsky, Univer- Drexel University (NIH), Enhancing Behavioral versity in St. Louis (NIH), Reproductive Scien- Erythematosus, 2 years, $90,002 • Yansheng sity of Virginia (NIH), Multimodal Develop- Weight Loss Interventions for Binge Eating tist Development Program (K12)-Scholar, Liu, Columbia University (NIH), Elucidation of mental Neurogenetics of Females with ASD, Disorder, 1.5 years, $21,663 • Giovanna Guerrero- 3 months, $29,100 • Rebecca Kamody, Society Combination Drug Perturbations by Molecular 3.8 years, $284,981 • Arijit Dutta, University Medina, University of Puerto Rico en Cayey of Pediatric Psychology, Society of Pediatric Profiling of Colorectal Cancer Signaling Net- of Texas Medical Branch, Mechanism of (NIH), Enhancing Research Training through Psychology Diversity Research Grant: Examin- works, 1 year, $90,701 • Jun Liu, University of R-loop Resolution in the Human Genome via Empowerment, Resilience, and Civic Engage- ing Disordered Eating and Weight Disparities Georgia (NIH), Role of Cardiolipin in Helico- the BRCA1-BARD1-SETX Axis, 1 year, $66,055 ment, 2 years, $168,980 • Seth Guller, Imperial Among Transgender and Gender Nonconform- bacter Pylori Flagellar Biogenesis, 5 years, Guido Falcone, Neurocritical Care Society, College School of Medicine (NIH), Modulation ing Youth, 1 year, $5,000 • Erdem Karatekin, $168,000 • Erin Longbrake, Cleveland Clinic A Cloud Computing-based, Fully Automated of Trophoblast Differentiation and Function University of Nebraska Medical Center (NIH), Foundation, Central Vein in Multiple Sclerosis Imaging Pipeline to Evaluate Perihematomal by Maternal Immune Cell Exosomes, 1.7 years, Regulation of Photoreceptor Neurotransmis- Pilot Study, 2 years, $12,500 • Patricia LoRusso, Edema in Intracerebral Hemorrhage, 1 year, $117,396 • Junjie Guo, Brain & Behavior sion, 1.5 years, $198,233 • Joy Kaufman, State Translational Genomics Research Institute $77,000; University of California, Irvine Research Foundation (formerly NARSAD), Role of CT Dept of Children and Family Services (TGen) (NIH), Individualized Monitoring of (NIH), Genetic Variation, Stress, and Func- of FMRP in Synaptic Localization of Neuronal (SAMHSA), Evaluation of Connecticut Treatment Response and Resistance in tional Outcomes after Stroke Rehabilitation/ RNAs, 2 years, $70,000 • Junjie Guo, Muscular Network of Care (CONNECT) Extension, Patients with Metastatic Melanoma, 1.5 years, The STRONG Study, 1.2 years, $17,588 • Shelli Dystrophy Association, Molecular Determi- 1 year, $112,687 • Alfred Kaye, Brain & Behavior $50,250 • Jiesi Luo, American Heart Associa- Farhadian, American Federation for Aging nants of Repeat RNA Foci Formation in Research Foundation (formerly NARSAD), tion, Xenogeneic-free Readily Available Tissue Research, Neurocognitive Impairment in C9ORF72-associated ALS, 3 years, $297,678 Circuit Mechanisms of a Pupillary Biomarker Engineered Blood Vessel from Human Induced Older Adults with HIV Infection: A Single Cell David Hafler, National Multiple Sclerosis for Stress-induced Hyperarousal, 2 years, Pluripotent Stem Cells, 2 years, $114,368 Approach, 2 years, $120,000; Robert E Leet Society, Longitudinal, Single-cell Assessment $70,000 • Benjamin Kelmendi, Brain & Behav- Steven Marans, New Alliance Foundation, and Clara Guthrie Patterson Trust, Bank of to Define the Mechanism of B Cell Depletion ior Research Foundation (formerly NARSAD), Child Development-Community Policing America, N.A., Trustee, Central Nervous Therapy in Multiple Sclerosis, 3 years, The Effects of MDMA on Prefrontal and Engagement, 1 year, $5,000; New Haven Dept. System Immune Activation During Virologi- $825,000 • Brendan Hare, Brain & Behavior Amygdala Activation in Post-traumatic Stress of Police Service, Protecting and Serving Train- cally Suppressed HIV, 2 years, $90,000 Research Foundation (formerly NARSAD), Disorder, 2 years, $69,089 • Trace Kershaw, ing for the New Haven Police Department, Liana Fasching, Tourette Association of Establishing Medial Prefrontal Cortex Rapid University of Maryland, Baltimore County 8 months, $5,200; New Haven Dept. of Police America (formerly Tourette Association), Antidepressant Circuits, 2 years, $70,000 (NIH), Preventing HIV/AIDS by Building Capac- Service, Protecting and Serving: Enhancing Law Single Nuclei Transcriptome Analysis of Annie Harper, Fahs-Beck Fund for Research ity to Reduce Stigma Among Providers for Enforcement Response to Children Exposed to Human Striatal Interneurons in Tourette Syn- and Experimentation at The New York Com- Pregnant Women in Rural Haiti, 1.8 years, Violence, 5 months, $7,150 • Molly Markowitz, drome, 1 year, $50,000 • Michelle Ferreira, munity Trust, Criminal Justice Related Debt $25,900 • Brigid Killelea, Breast Cancer Alli- American Academy of Pediatrics, Financial Melanoma Research Foundation, Evaluating and Mental Health: Barriers to Re-entry and ance, Interdisciplinary Breast Fellowship, 1 year, Wellness in a Medical Home, 1 year, $2,000 the Role of the COX2/PGE2 Pathway in Anti- Recovery, 2 years, $20,000 • Shilpa Hat- $75,000 • Robert King, University of Califor- David Matuskey, Brain & Behavior Research melanoma Immunity, 1 year, $3,000 • David tangadi, Hyundai Hope on Wheels, Signature nia, San Francisco (NIH), 2/7-Collaborative Foundation (formerly NARSAD), PET Imaging

8 www.medicineatyale.org of Synaptic Density in Autism Spectrum Disor- Dysfunction in Critically Ill Children, 2 years, Mitochondrial Dynamics in Female Reproduc- Aneurysm, 2 years, $114,368 • Richard Torres, der, 2 years, $70,000 • Linda Mayes, The Irving $62,393 • Margaret Pisani, Brigham and tion, 2 years, $351,250 • Dongju Seo, Peter F. Applikate Technologies (NIH), New Instrument Harris Foundation, Approach to Training and Women’s Hospital (NIH), Epidemiology and McManus Charitable Trust, The Development and Methods for Fast, Diagnostic-Quality His- Relationship to Infant Mental Health Commu- Risk of Antipsychotic Use in Hospitalized of Technology-Assisted Alcoholism Preven- tology of Un-embedded Bone Marrow and nity, 3 years, $345,000; Boston Medical Center, Elderly with Delirium, 1 year, $16,951 • David tion, 2 years, $49,999 • Nenad Sestan, Simons Lymph Node Specimens, 1 year, $37,999 Improving Preterm Outcomes by Safeguarding Pitt, Cornell University, Joan and Sanford I. Foundation, Gene Regulatory Control of Pre- Mariam Totonchy, American Society for Der- Maternal Mental Health, 1 year, $40,798 Weill Medical College of (NIH), No-Gd MRI for frontal Cortex Development and Evolution, matologic Surgery, Defining Perineural Inva- Adam Mecca, American Brain Foundation, Monitoring Disease Status in Multiple Sclero- 3 years, $825,000 • Nenad Sestan, Sirisha sion in Cutaneous Squamous Cell Carcinoma, Investigation of Molecular Changes in mGluR5 sis, 4.9 years, $146,263 • Christopher Pittenger, Pochareddy, Joan and Sanford I. Weill Medical 8 months, $6,900 • Jeffrey Townsend, Society and SV2A to Study Synaptic Alterations in University of Utah (NIH), Exploring the Role of College of Cornell University (NIH), The Spa- for Molecular Biology & Evolution, SMBE Alzheimer’s Disease Using PET, 1.3 years, Neurosteroids in Tic Modulation, 2 years, tiotemporal Landscape of the Human Brain Satellite Workshop Proposal, 1 year, $35,800 $3,410 • Eric Meffre, Lupus Research Alliance $122,446 • Krystal Pollitt, University of Mas- Epitranscriptome, 1.8 years, $250,000 • Lokesh Amelia Trant, Diva International, Understand- (formally: Alliance for Lupus Research), sachusetts Amherst, Public Health Assess- Sharma, American Thoracic Society, Mecha- ing Access to Menstrual Products in New PTPN22 Function in Human B Cells and Inhibi- ment for Transportation Projects, 1.6 years, nisms of Bacterial Dissemination in Lung Haven: Patient Interviews, 2 years, $1,000 tion to Reset Tolerance in SLE, 3 years, $43,000 • Zorana Pringle, Ontario Hospital Infection with Klebsiella pneumoniae, 1 year, Kathi Traugh, Elaine O’Keefe, Boston Univer- $552,706 • Saral Mehra, Medical Device Busi- Association, Emotion Revolution in the Work- $40,000 • Albert Shaw, Boston Children’s sity (DHHS), New England Public Health Train- ness Services, Educational Grant Fellowship, place Initiative: Partnership between the Yale Hospital (NIH), Service Core 2: Proteomics ing Center, 4 years, $500,000 • Jasmine 1 year, $20,250 • Andrew Miranker, Richard Center for Emotional Intelligence and Ontario Core—Study Flu Vaccine-induced Changes in Travers, University of Pennsylvania (NIH), Lounsbery Foundation, AMBER: Analysis of Hospital Association, 1.1 years, $250,000 Plasma Proteome, 1.3 years, $10,368 • Beverley Center for Improving CAre Delivery for the Microbiome Embedded in aRt, 1.5 years, Caihong Qiu, Chinese Academy of Science, Sheares, Wayne State University (NIH), Trans- Aging (CICADA), 1.3 years, $35,641 • Marietta $119,812 • Pramod Mistry, Genzyme Corpora- Service Contract between Chinese Academy lating an Efficacious Illness Management Vazquez, Brigham and Women’s Hospital tion, Yale Center of Excellence in Clinical Trans- of Sciences, Institute of Zoology and Yale Intervention for African American Youth with (DHHS), Reducing the Morbidity and Mortality lational Research in Gaucher Disease, 3.5 years, University on behalf of Yale Stem Cell Center Poorly Controlled Asthma to Real World Due to Acute Febrile Illnesses in Central $2,860,948 • Angela Montgomery, University hESC/iPSC Core, 1 year, $19,000 • Anthony Settings, 1.5 years, $16,578 • Mohamed Sherif, America and the Dominican Republic, 1 year, of North Carolina at Chapel Hill (NIH), Environ- Rampello, Dystonia Medical Research Founda- Robert E. Leet and Clara Guthrie Patterson $37,965 • Arjun Venkatesh, American College ment, Epigenetics, Neurodevelopment & tion, A Genetic Approach toward Identifying Trust, Bank of America, N.A., Trustee, An Elec- of Emergency Physicians (ACEP), ACEP CEDR Health of Extremely Preterm Children, 5 years, Torsin Function in Relation to DYT1 Dystonia, trophysiological Investigation of Mechanisms Measure Validation (2017 Dataset), 6 months, $175,900 • Ruth Montgomery, Children’s Hos- 2 years, $100,000 • Yusuf Ransome, Brown Underlying the Rapid Antidepressant Effect of $51,210 • Merceditas Villanueva, New Haven, pital Corporation, (formerly CHB), Systems University (NIH), The Role of Faith Institutions, Ketamine, 2 years, $90,000 • Kevin Sheth, CT, City of New Haven (DHHS), Ryan White Biology to Identify Biomarkers of Neonatal and Religion and Spirituality (R/S) Experiences Serena Spudich, Massachusetts General Hos- Part A HIV/AIDS Service Continuum, 1 year, Vaccine Immunogenicity, 3 months, $10,368 in HIV Prevention and Care Strategies Among pital (NIH), Yale Clinical Site: Investigations $1,465,277 • Chantal Vogels, Netherlands Christopher Moore, Phillips Research North African American Men Who Have Sex With for Improved Neurological Treatments at Yale Organisation for Scientific Research, Impact America, Automated B-line Assessment in Men, 2 years, $19,000 • Uma Reddy, University (INFINITY), 5 years, $1,675,000 • Kevin Sheth, of Zika Virus Evolution on Transmission Lung Ultrasound, 1 year, $98,899 • Walther of Alabama at Birmingham (NIH), Antihyper- Mark Alberts, Karen Furie, University of Cin- Potential by Mosquitoes, 2 years, $151,766 Mothes, Drexel University (NIH), Structure- tensive Therapy for Mild Chronic Hypertension cinnati (NIH), Southern New England Partner- Fred Volkmar, The Nancy Taylor Foundation Based Antagonism of HIV-1 Envelope Function during Pregnancy: A Pragmatic Multicenter ship in Stroke Research, Innovation and Treat- for Chronic Diseases, Diagnostic Stability and in Cell Entry, 2 years, $327,443 • Angus Nairn, Randomized Trial (CHAP Project), 1 year, $132,241 ment (SPIRIT), 5 years, $1,670,705 • Brian Early Childhood Predictors of Outcome in Massachusetts General Hospital (NIH), The Carrie Redlich, State of CT Dept of Labor, Pro- Shuch, Ranjit Bindra, The Hope Foundation , Autism Spectrum Disorders, 1 year, $108,000 Massachusetts and Yale ADRC Collaborative posal for the Provision of Occupational Health Identification and Characterization of Jacob Wallace, Harvard Medical School, The Proteomic Biofluid Biomarker Discovery Clinic, 1 year, $78,203 • David Reiss, Regents of Oncometabolite-induced DNA Repair Defects Impact of Medicaid Plans on Access to and Program, 1.7 years, $737,063 • Anirvan Nandy, the University of California (NIH), Interdisci- in Sporadic Papillary Kidney Cancer, 1 year, Quality of SUD Treatment, 2.8 years, $12,951 E. Matilda Ziegler Foundation for the Blind, plinary Research Network on Early Adversity & $200,000 • Dena Simmons, Charlotte- Emily Wang, Columbia University, Rikers The Impact of Eye-movements on Neural Later Life Reversibility—Administrative Supple- Mecklenburg Schools Board of Education, Island Longitudinal Study, 1 year, $50,000; San Dynamics and Cortical Organization, 3 years, ment, 1.1 years, $106,121 • Chin Reyes, Spencer Charlotte NC RULER Training, 1 year, $340,826; Francisco Public Health Foundation, Expand- $240,000 • Onyema Ogbuagu, National Foundation, The Silent Struggle: Exploring the EdAdvance, EdAdvance RULER Training, 1 year, ing the TCN Network in California, 2.6 years, Academy of Sciences, Assistance in Manage- Role of Social and Emotional Interactions in the $160,500; Oakland Schools, Oakland Schools $391.824 • Samuel Wilkinson, American ment of USAID’s Partnerships with NSF and Language Development of Young English Lan- Service Agreement, 1 year, $23,000 • Matthew Foundation for Suicide Prevention, Effects of Related Activities to Promote Global S&T guage Learners, 1.5 years, $49,987 • David Simon, Ono Pharma Foundation, Disulfide Electroconvulsive Therapy on Suicide Partnerships (PEER Health), 1.5 years, $119,099 Rimm, Breast Cancer Research Foundation, Tethering to Discover Small-Molecule Ligands Attempts in Geriatric Patients with Depres- Emily Olfson, American Academy of Child and Targeted and Immune Therapies in Breast for RNAs Across the Mammalian Transcrip- sion, 2 years, $84,706 • Francis Wilson, Johns Adolescent Psychiatry, Pilot Study Investigat- Cancer, 1 year, $250,000; Johns Hopkins Uni- tome, 1 year, $172,500 • Jonathan Siner, North- Hopkins University (NIH), AKI Matched Phe- ing the Role of De Novo Genetic Variants in versity (NIH), PD-1/PD-L1 Modulation in Shore University HealthSystem (NIH), A Novel notype Linked Evaluation with Tissue Trichotillomania, 1.3 years, $15,000 • John Cancer Therapy, 1 year, $51,325 • Aaron Ring, Data Science and Network Analysis Approach (AMPLE-Tissue), 1 year, $51,963 • Adam Pachankis, Rutgers, the State University of University of Minnesota (DoD), Mechanisms to Quantifying Facilitators and Barriers of Low Wisnewski, American Chemistry Council, New Jersey (NIH), Building Mobile Health HIV of Resistance to Immunotherapy in Osteosar- Tidal Volume Ventilation in an International Glutathione Conjugates of Aliphatic Polyiso- Prevention and Mental Health in Low-resource coma, 2 years, $25,781; University of Minne- Consortium of Medical Centers, 1.7 years, cyanates: Generation and Characterization Settings, 1.8 years, $335,273 • A. David Paltiel, sota, Novel Immunotherapy for Sarcomas $157,303 • Courtney Smith, Pharmaceutical In Vitro, 1 year, $81,868 • Ambrose Wong, Massachusetts General Hospital (NIH), Opti- using Combination Oncolytic VSV and IL-18 Research & Manufacturers of America Society for Academic Emergency Medicine, mizing HIV Care in Less Developed Countries, Superkine, 1 year, $40,700, Dr. Ralph and (PhRMA) Foundation, Understanding the Well-Being and Mistreatment of Sexual and 1.5 years, $50,366; Stanford University (NIH), Marian Falk Medical Research Trust Bank of Molecular Mechanism of TIM3 Signaling, Gender Minority Medical Students, 1 year, Making Better Decisions: Policy Modeling for America, N.A., Trustee, Breaking the Vicious 2 years, $40,000 • Erica Spatz, Baystate $3,000 • Yinyu Wu, American Heart Associ- AIDS and Drug Abuse, 4.8 years, $608,849 Cycle of Necroptosis and Inflammation with a Medical Center (NIH), Identifying Effective ation, MicroRNA-223 Regulation of Hemo- Michael Pantalon, Gail D’Onofrio, Yale New Therapeutic “Molecular Shroud”, 1 year, Strategies Used by Medicare Accountable genic Endothelial Cell Specification via Haven Health System (SAMHSA), Project $300,000 • Kurt Roberts, Foundation for Sur- Care Organizations to Improve Outcomes for N-glycosylation, 2 years, $53,688 • Ke Xu, ASSERT, 5 years, $1,121,188 • Sunil Parikh, gical Fellowships, Grant Acceptance and Patients With Heart Failure: A Mixed-Methods Research Triangle Institute (NIH), Genomic Colorado State University (NIH), Repeat Iver- Agreement 2018-2019. Yale Bariatric MIS Fel- Study, 3.8 years, $340,764 • Donna Spiegel- or Nucleomic Information to Understand HIV mectin Mass Drug Administrations for Malaria lowship, 1 year, $20,000 • Brita Roy, Hennepin man, Harvard School of Public Health (NIH), Latency in Individuals with Substance Use Control II (RIMDAMAL II): A Double-blind Healthcare Research Institute, Reframing The Moderate Alcohol and Cardiovascular Disorders, 1.7 years, $381,540 • Henry Yaggi, Cluster Randomized Trial for Integrated Healthcare Through the Lens of Co-production Health Trial (Harvard Biostatistical and Bio- Johns Hopkins University (NIH), Sleep Apnea Control of Malaria, 1.5 years, $167,500 • Bhinna (RHeLaunCh), 1 year, $33,676 • Changwan Ryu, specimen Core), 1 year, $10,362 • Serena Treatment with Positive Airway Pressure for Park, American Psychiatric Association, Parker B. Francis Foundation, Mitochondrial Spudich, Henry M. Jackson Foundation for the Prevention of Diabetes Mellitus, 11 months, Mental Health Resources for Refugees/ DNA as a Novel Biomarker in Idiopathic Pulmo- Advancement of Military Medicine (DoD), $19,690 • Qin Yan, Breast Cancer Alliance, Asylees in Conjunction with the International nary Fibrosis, 3 years, $156,000; Foundation for Study of NeuroHIV Cure Consortium (Proto- Targeting KDM5B Histone Demethylase to Rescue Committee (IRC), 1 year, $19,210 Sarcoidosis Research, Association Between cols ls: R 254, RV397, RV398, RV405, RV412), Boost Antitumor Immune Response in Breast Christine Park, Frederick A. Coller Surgical Extracellular Mitochondrial DNA and Poor 1 year, $211,050; University of California, Los Cancer, 1 year, $100,000 • Chongguang Yang, Society, Targeting Small Intestinal Serotonin Clinical Outcomes in African American Angeles (NIH), AIDS Clinical Trials Group Robert E. Leet and Clara Guthrie Patterson Receptors as Therapy for Intestinal Failure, Patients with Sarcoidosis, 2 years, $250,000 (ACTG), 2 years, $6,206 • Derek Steinbacher, Trust, Bank of America, N.A., Trustee, The 1.2 years, $15,000 • Abhijit Patel, Alessandro Fatima Saddouk, American Heart Association, Medical Device Business Services, Educational Role of Internal Migration in the Transmis- Santin, The Honorable Tina Brozman Founda- Reversal of Vascular Remodeling in Pulmonary Grant Fellowship, 1 year, $52,638; DePuy sion Dynamics of Multidrug-resistant Tuber- tion for Ovarian Cancer Research, Inte- Hypertension, 2 years, $104,060 • Gerard Synthes, Educational Grant Clinical Fellowship, culosis in Urban China, 2 years, $90,000 grated Analysis of Circulating Tumor DNA Sanacora, Amyotrophic Lateral Sclerosis Asso- 1 year, $21,000 • Mario Strazzabosco, PSC Sarah Yip, Brain & Behavior Research Foun- and Protein Biomarkers for Early Detec- ciation (ALS Association), Characterization of Partners Seeking a Cure, Upregulation of dation (formerly NARSAD), Neuromarkers of tion of Ovarian Cancer, 2 years, $200,000 Mitochondrial Function and Neuron-Glial (Glu- Biliary Epithelia Innate Immune Responses in Opioid Relapse in Chronic Pain, 2 years, Candice Paulsen, Rita Allen Foundation, tamate/GABA) Neurotransmitter Cycling in a PSC, 1.3 years, $32,384 • Stephen Strittmatter, $69,212 • Bryan Young, Foundation for Sar- Uncovering the Regulation of TRPA1 by Irri- Mouse Model (SOD1-G93A) of Amyotrophic Dr. Ralph and Marian Falk Medical Research coidosis Research, Novel Biomarkers and tants, Cofactors, and Proteins, 3 years, Lateral Sclerosis using 1H-[13C] NMR Spec- Trust Bank of America, N.A., Trustee, Fyn Tracers for Sarcoid Disease Activity, 2 years, $150,000 • Paulina Pawlica, American Cancer troscopy, 1.1 years, $99,938 • Anjali Sankar, AIM Kinase Inhibition for Tauopathy in Dementia $250,000 • Heping Zhang, University of Col- Society, Regulation of microRNA Populations Youth Mental Health, Corticolimbic System and Glaucoma, 2 years, $1,000,000 • Scott orado Denver (NIH), The Clinical Research/ by Oncogenic Viruses, 2 years, $54,000 • Sam Functioning during Emotion Regulation in Strobel, Howard Hughes Medical Institute, Reproductive Scientist Training Program Payabvash, Gordon Sze, Radiological Society Youth with Bipolar Disorder and its Changes Building Bridges for Inclusive Excellence, (CREST), 1.7 years, $108,831 • Yalan Zhang, of North America, Grant Transfer Request with a Targeted Psychobehavioral Interven- 2.1 years, $49,600 • Xiaolei Su, Andrew National Ataxia Foundation, Investigating Evaluation of White Matter Connectome tion, 1.2 years, $63,849 • Carolyn Sartor, Peter McDonough B+ Foundation, Mechanism of the Molecular Mechanism of Neurodegener- Changes in Children with Sensory Processing F. McManus Charitable Trust, Refining Etiolog- Chimeric Antigen Receptor Activation in Pedi- ation in Spinocerebellar Ataxia Type 13, 1 year, Disorders using EDI, 1 year, $8,193 • Godfrey ical Models of Drinking Behaviors in Black atric Cancer Immunotherapy, 2 years, $50,000 • Hang Zhou, Brain & Behavior Pearlson, Hartford Hospital (NIH), Neuroim- Adolescents and Young Adults through Con- $150,000; Charles H. Hood Foundation, Inc., Research Foundation (formerly NARSAD), aging Predictors of Bariatric Surgical Out- sideration of Understudied Risk and Protective Boston, MA, Mechanism of Chimeric Antigen Identifying Genetic Risks for Comorbid Major comes, 1.4 years, $85,649 • Bruno Balbo Factors, 1 year, $49,999 • Dustin Scheinost, Receptor Activation in Cancer Immunotherapy, Depression and Substance Use Disorders by Pedroso, PKD Foundation for Research in Poly- Columbia University (NIH), Intergenerational 2 years, $165,000 • Amrita Sule, American Large-Scale Whole Exome Sequencing, cystic Kidney Disease, Targeting the Cell Cycle Transmission of deficits in Self-Regulatory Association for Cancer Research, Targeting 2 years, $70,000 • Melissa Zhou, Consor- as a Potential Treatment for ADPKD: The Role Control, 1.3 years, $88,454 • Michael Schilsky, Oncometabolite-producing Cancers with DNA tium of Multiple Sclerosis Centers, Out- of Cyclin-Dependent Kinase 1, 2 years, Wilson Disease Association, Wilson Disease Repair Inhibitors, 3 years, $225,000 • Tami comes Following a First Clinical Event in Chil- $120,000 • Peter Peduzzi, University of Cali- Registry Study, 4 years, $2,806,044 • Mark Sullivan, University of Texas Health Science dren with the Radiologically Isolated fornia, Los Angeles (NIH), Pragmatic Trial of Schlesinger, University of Wisconsin-Madison, Center at San Antonio (NIH), Daily Dynamics Syndrome, 8 months, $5,000 • Xin Zhou, the Effectiveness and Cost-Effectiveness of Patients Experiences with Breast Cancer, 1 year, and Long-term Trajectories of Elder Abuse and Harvard School of Public Health (NIH), Trial Dementia Care, 11 months, $703,096 • Dana $33,407 • Martin Schwartz, Foundation Neglect in Family Caregiving, 1.7 years, $60,183 of Vitamin D Supplementation to Prevent TB Pepe, Infectious Diseases Society of America, Leducq for Cardiovascular Research (formally Huanxing Sun, American Thoracic Society, Infection in Schoolchildren, 1.5 years, $20,125 Expanding Utilization of Targeted Assessment Foundation Leducq), Transcription Factor Mitochondrial DNA and Fibroblasts in SSc-ILD, Andrey Zinchuk, Parker B. Francis Founda- for Prevention (TAP) Strategy in Connecticut, Klf2 and Cardiovascular Disease, 5 years, 1 year, $40,000 • Jakub Toczek, American tion, Novel physIologic predictors of adher- 1 year, $100,000 • Richard Pierce, University of $1,162,525 Emre Seli, Foundation for Embryonic Heart Association, Molecular Imaging of enCE to Positive Airway Pressure: NICEPAP, Utah (NIH), Mechanisms of Endothelial Cell Competence, Investigation of the Role of Phagocytic Activity in Abdominal Aortic 3 years, $192,450

Medicine@Yale November/December 2019 9 Child Study Center brings clinical care under one roof

Former telephone company The building’s work areas, We also have room for growth. And in America can learn and succeed,” building, once foreboding, is 53,000 square feet total, are more we bring programs together that added U.S. Representative Rosa than triple the combined space of heretofore did not have the opportu- DeLauro. “That is what you will now bright and welcoming CSC’s three prior facilities, which nity to collaborate.” continue to do at this facility.” were on York and Temple Streets and At the official ribbon-cutting Mayes says it is great to see the The Yale Child Study Center (CSC) on South Frontage Road. Linda C. on October 4, Robert J. Alpern, excited look on children’s faces as has dedicated a new behavioral Mayes, MD, Arnold Gesell Professor MD, dean and Ensign Professor of they walk through the doors of the health care facility at 350 George of Child Psychiatry, Pediatrics, and Medicine, said the building is a space new space. “That’s why we did it. I Street in New Haven that puts Psychology, and chair of the CSC, transformed. He recalled first seeing feel that’s what makes it worthwhile,” its clinical and community-based says the larger size is just one of its it a few years ago, “when it was a she says. “I think it’s the respect they operations all under one roof, advantages. “Before, our families had building that the telephone company feel by the beauty of it. It doesn’t feel and provides a bright space that to come to different sites. A family used for phone lines and it had no traditionally medical. It feels welcom- is being warmly praised as a wel- might go to one building, and then windows and it looked like a bunker.” ing and caring.” coming place for young patients they would have to come all the way Now there are large windows on all Erin Warnick, PhD, associate and their families. to another building,” she explains. sides, along with original artwork, research scientist and CSC’s lead books donated by Scholastic Pub- of clinical operations, organized lishing, plus well-placed lighting the planning effort for what was a and other architectural touches by massive project. “We imagined, how the firm of Svigals + Partners that could we build a space that really enhance the quality of the care being supports the work that we’re doing delivered. “This will really be the for our community?” Warnick said home that the Child Study Center has at the ribbon-cutting. “Thank you always deserved,” Alpern proclaimed. across the board to all the members Marna Borgstrom, CEO of Yale of our community who contributed New Haven Health, celebrated the big ideas, little ideas. As you walk opening as one more example of the through the space, you can see that seamlessness of care between the all of these ideas were incorporated hospital system and the School of into the plans because each of them Medicine. “Our patients see us as made a difference and each of those one organization, and Linda [Mayes] contributions serves to create what has been key to helping to lead this this space really is today.” transformation for the entire medical Approximately 225 people will center,” Borgstrom said. “We owe her work in the new facility, includ- incredible gratitude because I don’t ing physicians, psychologists, social think we would be here without her.” workers, pediatricians, and staff. The The children of New Haven and building will also be home to the nearby communities will be very Center for Emotional Intelligence, well served, said New Haven Mayor which previously occupied space Toni Harp. “The children who come on Edwards Street, as well as all of

robert a. lisak here deserve space that lets them the Child Study Center’s in-home The Yale Child Study Center has consolidated its “Clinicians and scholars in those dif- know that you respect them, that programs, the MOMS Partnership, clinical and community-based operations, formerly ferent sites had fewer opportunities you have high expectations, and that and Elevate, a policy lab. The Yale divided among several New Haven locations, into a single building at 350 George Street. With modern to interact with and learn from one they’re going to be better because Child Study Center receives approxi- lighting and other innovative design features, the another. Bringing everyone together they came here.” mately 60,000 patient visits each new facility has been praised as especially welcom- in one space allows them to work “You stood up for the principle year. CSC’s research operations and ing for young patients and their families. Dean Robert Alpern praises it as “the home that the together more effectively. It’s giving long before it became fashionable, administration remain at 230 South Child Study Center has always deserved.” patients one door to come through. that given the chance every child Frontage Road.

// Autoimmune (page 1) and technol- venture capital firms, to evaluate at Yale and joined the faculty in beg for support,” says Craft. “The ogy to alleviate autoimmune dis- proposals from Yale’s many schools 1985, where he runs a laboratory Coltons’ vision and generous gift orders, improving lives of patients and academic disciplines. devoted to the study of immuno- will enable us to provide that sup- and families. Craft and the committee will logical diseases, with particular port to move forward ideas that “Finding the keys to autoim- select and monitor unique, well- attention to SLE. He also served as show real promise.” mune disease is one of the most defined projects that show the most section chief of rheumatology until “The new center will have a vexing challenges in science,” say the promise, making awards in two cat- 2018, when he stepped down to substantial, broad impact on the Coltons. “It would do so much for egories: pilot grants for exploratory focus on his research. Department of Immunobiology, en- humankind to uncover its causes, and proof-of-concept activities; and He has been captivated by the abling exciting new ideas to be tested and ultimately to develop effective development grants for more firmly complexities of autoimmune disease and accelerating the development treatments. We think that Joe Craft grounded projects. Development since medical school. “As a first-year of potential new therapeutics for and his Yale colleagues are uniquely grants may be extensions of success- student, the first patient I ever saw autoimmune diseases,” adds David equipped to do this work, and that ful pilot grants, or other new projects had lupus,” he says. “I’ve thought Schatz, PhD, chair and Waldemar the Colton Center will be a perfect with great potential. about that for years—how we could Von Zedtwitz Professor of Immuno- vehicle through which to succeed.” To ensure an appropriate breadth have understood more about her dis- biology, and professor of molecular The new center’s mission is to of proposals for these awards, the ease and provided better treatment.” biophysics and biochemistry. “We are identify and support innovative, center will also evaluate and poten- As international leaders in particularly excited by the opportu- high-impact research projects with tially support ideas that are submit- immunology and autoimmunity nity to merge basic and translational the potential for translation into ted to other funding sources at Yale research, Yale scientists have made research to benefit patients.” therapies. To nurture the advance- that are dedicated to promoting many important discoveries that “Throughout the School of ment of early-stage discoveries, the biomedical innovation. A yearly sym- advance understanding of immune Medicine, there has long been an center will support the proof-of-con- posium will bring together investiga- system dysfunction. The new center emphasis on understanding im- cept and validation studies that are tors, donors, philanthropic advisors, will encourage cross-disciplinary, munological diseases and thinking crucial in transforming novel ideas advisory committee members, and investigator-initiated research, active- creatively about autoimmune dis- into treatments, devices, and cures. Yale leadership to review the progress ly bridging the gaps between research ease to find new treatments,” says Craft will work closely with an of funded projects. and application. It will provide strate- Robert J. Alpern, MD, dean and advisory committee composed of Craft is well positioned to lead gic resources to ensure that research Ensign Professor of Medicine. “This experts in autoimmunity research the center. Autoimmune disease has with commercial relevance does not center will accelerate our efforts, from Yale as well as other aca- been the focus of his work, both stall due to lack of funding. with the promise of improving the demic institutions and members of clinically and in the lab. He trained “We’re looking for really novel quality of life for millions who suf- the pharmaceutical industry and in rheumatology and immunology ideas, and sometimes novel ideas fer from autoimmune diseases.”

10 www.medicineatyale.org Palliative care receives recognition and a professorship

Kapo’s work highlights the fighting death. During the last year of gave her Kapo’s number, and Vlock principle of patient-centered care as a importance of easing pain his life as he battled prostate cancer, was brought back to New Haven, foundation of medicine. I would sug- Nuland received palliative care from where Kapo cared for him until his gest to you that few fields exemplify and discomfort of illness Kapo and her team. death on September 29, 2017. patient-centered care better than pal- “Having been with Shep in all “Anyone who knew Michael knew liative medicine.” When Jennifer Kapo, MD, arrived that was going on, I was used to he was an individual person and The event’s keynote speaker, at Yale in 2012, palliative care was being in the clinic, and it’s one of the had his own way of doing things,” Diane E. Meier, MD, a geriatrician widely considered an afterthought, a most dehumanizing places in the Pritzker said. “Jen met him where at Mount Sinai Health System in therapy reserved for terminally ill pa- world,” says Sarah Nuland, his wid- he was and helped us navigate that New York and founder/director of tients who had exhausted both options ow. “Jen Kapo came into the room, phase.” Inspired by the impact of the nationally recognized Center to and hope. After she became inaugural and the temperature changed. She palliative medicine on her husband’s Advance Palliative Care, stressed the chief of the Yale Palliative Care Pro- was warm, kind, thoughtful. And final weeks of life, gram and the Yale New Haven Hospi- she didn’t look at the computer. She Pritzker decided tal Palliative Care Service, Kapo built looked into the eyes of my husband.” in June 2018 to the program from a four-person unit As he wished, Nuland died in his expand her initial that received roughly 300 consults per home in Hamden on March 3, 2014. gift and endow the year into a service that has received Inspired by Kapo and seeking a way professorship. national renown. Her interprofes- to commemorate her husband, Sarah On a warm- sional team now consists of 30 people, Nuland decided to start the Nuland winded June 25, including two social workers and two Foundation, a nonprofit dedicated to 2019, some 150 chaplains, and other professionals advancing palliative care’s role in health people from across including an art therapist. care and to educating underserved the Yale com- All deliver the essence of what communities about it. Emblazoned as munity, including palliative care is—a specialized form of the organization’s motto are words she the families and medical care focused on relieving the had found scribbled into an advance friends of Kapo, symptoms and stress of a serious ill- print edition of How We Die, tucked Nuland, and ness. It is appropriate at any age and at away beside her husband’s chipped Vlock, gathered any stage, and one can receive it along pine writing desk: “The purpose of the under the dark kaufmancarl with curative treatment. The goal is art of medicine is not primarily to cure timber beams of the Harvey Cush- At a ceremony celebrating the establishment of the Sherwin B. Nuland and Michael K. Vlock Profes- to improve the patient’s quality of life. disease or to fight death, but to relieve ing/John Hay Whitney Yale Medical sorship of Palliative Medicine, the chair’s inaugural Today, Kapo’s program treats more human suffering.” Historical Library to celebrate the occupant, Jennifer Kapo, stands between donors than 3,000 new patients per year at One of Sarah Nuland’s chief goals establishment of the Sherwin B. Nu- Sarah Nuland (left) and Karen Pritzker. 13 sites across Connecticut. for the foundation was to establish land and Michael K. Vlock Professor- importance of training physicians in Among the patients Kapo cared an endowed professorship of pallia- ship of Palliative Medicine. palliative medicine and applauded for at Yale were Sherwin B. Nuland, tive medicine at Yale. She approached Robert J. Alpern, MD, dean and Yale’s efforts. “This is a commitment MD ’55, and Michael K. Vlock. These many of her close friends for fund- Ensign Professor of Medicine, warm- from Yale School of Medicine to say men would serve as the inspiration ing. One was Karen Pritzker, a local ly remembered the two men, recalling this is a core part of the practice of for Yale’s first endowed professorship philanthropist and investor. Pritzker Nuland’s strong-willed commitment medicine and health care. It is as for palliative medicine, a position to and her husband Michael Vlock had to medicine and Vlock’s dedication to important as the management of which Kapo was appointed in April of previously supported Yale New Haven the New Haven community. He also hypertension or diabetes.” this year. Hospital’s neonatal intensive care commended Kapo for expanding and For Kapo, the professorship is a Nuland, known as Shep by unit, as well as other organizations strengthening Yale’s palliative care mark of legitimacy for palliative care those who were closest to him, was a including Teach for America and program. “It is Jen’s clinical excel- at Yale. “We will be able to think professor of surgery at Yale School of the Michael J. Fox Foundation for lence that really helped to inspire the about palliative care as woven into Medicine and also was a best-selling Parkinson’s Research. Pritzker and gift today,” he said. the fabric of the standard of care that author and bioethicist. In addition to Vlock discussed Nuland’s request, and It was within the cancer program we provide for all patients,” she said. mentoring medical students, he taught agreed they should contribute. at Yale New Haven Hospital that the “It’s not just a specialty to which we a freshman history of medicine semi- Nuland’s cause soon became Palliative Care Program began in refer patients when there’s nothing nar at Yale College. Nuland’s book personal to them. In early 2017, Vlock 2007. Charles S. Fuchs, MD, MPH, left to do, but rather one that’s truly How We Die: Reflections on Life’s Final was diagnosed with mesothelioma Richard Sackler and Jonathan Sackler integrated throughout the courses of Chapter, winner of the 1994 National and began a treatment plan at a hospi- Professor of Medicine (Medical On- all serious illness.” Book Award, candidly demystified, tal in New York. Seeing her husband’s cology), director of Yale Cancer Cen- “There is a lot of work to do to organ by organ, the process of dying vitality fading from the brutal inten- ter, and physician-in-chief of Smilow meet that goal,” she cautioned. “But and challenged the American health sity of the treatment, Pritzker sought Cancer Hospital, said, “Today’s cel- with this endowed chair, we’ll be able care system’s bullish obsession with out Sarah Nuland for advice. Nuland ebration recognizes the fundamental to work toward that.”

// Dean (page 1) 13 academic divi- medicine during her undergraduate Brown’s appointment followed Brown is well aware of the pressures sions, thrived. In addition to increas- days at Yale. “You follow your ques- an extensive search initiated by of pursuing increasingly competi- ing the number of faculty by almost tions where they take you,” she says President Peter Salovey, PhD ’86, tive grant funding and the growing 30% during her tenure as chair, she of her decision to specialize in clinical that was undertaken by a committee demands and financial pressure of recruited eight division directors, pharmacology. Her curiosity about the chaired by Lynn Cooley, PhD, dean providing clinical care, which she including four women, and increased renin-angiotensin-aldosterone system, of the Graduate School of Arts and believes have affected the way medi- the proportion of trainees and faculty which regulates blood pressure, led to Sciences, C.N.H. Long Professor of cal students and residents are trained. from groups traditionally underrep- discoveries on how that system affects Genetics, and professor of cell biology Her vision is to “return joy to the resented in medicine. glucose homeostasis as well as fibrino- and of molecular, cellular, and devel- work of academic medicine.” She expanded mentorship lysis (the breakdown of fibrin clots that opmental biology; and composed of Although still in what she terms resources for trainees and faculty result from coagulation); the cardiovas- diverse faculty and representatives the “early stages of the diagnostics” at immersed in research and estab- cular and renal effects of ACE inhibi- from across the School of Medicine, Yale, she would like to explore oppor- lished a career development program tors and other drugs used to control the university, and Yale New Haven tunities to develop physician-scientists for faculty focused on clinical care. blood pressure; and the mechanisms of Health. “It was clear to me from the who bridge discovery and patient care, Research funding overall in the angioedema (a swelling under the skin search committee that the members grow the medical school’s research department increased by 56% and or mucous membranes). Her research are passionate about making Yale a portfolio in support of the university’s funding from the National Institutes program has been continuously funded better place,” Brown says. strategic plan for science, and focus of Health (NIH) went up by 47%. by the NIH since 1993. On the clinical As to why she set her sights on on improving the work climate at Clinical activities also experienced an side, she has had a long career treating becoming dean, Brown says: “Many YSM, which will be an early prior- upswing, with outpatient visits grow- patients with resistant hypertension, people have given to me in my ity. “I think we need to stick to some ing by 59% and admissions by 25%. including those with such second- career. Medicine faces a number of fundamental values and goals,” she An interest in how things work ary causes of the condition as adrenal challenges that I would like to help says, “and that requires creativity to sparked Brown’s desire to study tumors and renal vascular disease. address.” As a physician-scientist, do within the current constraints.”

Medicine@Yale November/December 2019 11 Strobel is appointed provost of Yale University Horwich is 2020 Longtime medical school Co-recipient of faculty member will oversee Breakthrough Prize Yale academics and budget Arthur L. Horwich, MD, and colleague Scott A. Strobel, PhD, Henry Ford F. Ulrich Hartl, II Professor of Molecular Biophys- MD, from the Max ics and Biochemistry and a Howard Planck Institute, Hughes Medical Institute investiga- will share a $3 mil- tor, has been named the university’s lion Breakthrough next provost, effective January 1. The Prize, the richest provost is Yale’s chief academic and Arthur Horwich prize in the sciences. budgetary officer. Horwich, Sterling Professor of “From chairing the University Genetics at Yale School of Medicine and Science Strategy Committee to lead- an investigator at the Howard Hughes ing the development of the Poorvu dan renzetti Medical Institute, and Hartl, director of Center for Teaching and Learning, the Max Planck Institute of Biochemis- Scott has been an integral part of … and worked tirelessly in support Scott Strobel is Yale University’s incoming provost. try, are honored for their work describ- In his more than 20 years at the university, he has led our efforts to realize the university’s of our students. As provost, his aca- such top-level initiatives as the University Science ing the molecular machinery that folds mission of research, scholarship, demic and budgetary leadership will Strategy Committee, which he chaired. proteins into proper shapes within cells. education, preservation, and prac- extend to every part of Yale.” Proteins must be folded into proper tice,” President Peter Salovey, PhD Strobel earned his PhD from the grateful to President Salovey for the three-dimensional structure to carry ’86, wrote Nov. 6 in a campus-wide California Institute of Technology trust he places in me to help shape out their functions, which are crucial email announcing the appointment. under Peter Dervan, PhD ’72. He and shepherd Yale’s ambitious agen- to all life. The scientists have shown He has served as chair of the pursued postdoctoral research at the da. This university is on sure footing this folding inside cells does not occur Department of Molecular Biophysics University of Colorado with Thomas thanks to him and to Ben Polak, spontaneously, as previously believed, and Biochemistry (2006-2009), vice Cech, PhD, who shared the 1989 who has been a remarkable example but depends upon molecular “assis- president for West Campus planning Nobel Prize in Chemistry with Yale of integrity, discipline, commitment, tants” called chaperones. The misfold- and program development (2011- Professor Sidney Altman, PhD. and strategic acumen. I’ve benefitted ing of proteins has been implicated in 2019), deputy provost for teaching Since joining the Yale faculty in from his example, and I’m honored Alzheimer’s, Parkinson’s, Huntington’s, and learning (2014-2019), and vice 1995, Strobel has won awards for pro- to succeed him. and other neurodegenerative diseases. provost for science initiatives (2019). moting undergraduate education, men- “Yale has long epitomized intel- Horwich and Hartl have won Through these roles, Salovey toring graduate students, and leading lectual teamwork,” he continued. numerous awards for describing the wrote, “Scott has developed a research programs at the intersection of “The academic priorities we’re molecular basis of protein folding, profound appreciation for all parts chemistry and structural biology. pursuing together are as interde- including the prestigious Albert Lasker of Yale’s academic enterprise: arts, Strobel succeeds Ben Polak, PhD, pendent as they are distinct, and Basic Research Award. humanities, social science, and the provost since 2013. Polak, the that’s by design: The world calls for The Breakthrough Prize annually sciences and engineering. He has William C. Brainard Professor of Eco- people and approaches that break recognizes achievements in the life worked closely with the professional nomics and professor of management, boundaries to improve the world. sciences, fundamental physics, and schools and the FAS [Faculty of Arts will return to the faculty full time. I look forward to supporting our mathematics, disciplines that “ask & Sciences]. He has partnered with “It’s a special honor to be offered amazing faculty in the full expres- the biggest questions and seek the faculty from across the university this role,” Strobel said, “and I’m sion of that work.” deepest explanations.”

National Academy of Medicine elects six new members from Yale Basic science, clinical care, National Academy of Engineering of more than 30 proteins to infect and and public health are all to provide independent, objective replicate within host cells. analysis and advice to the nation • Akiko Iwasaki, PhD, Waldemar Von represented by the honorees and conduct other activities to solve Zedtwitz Professor of Immunobiol- complex problems and inform public ogy, professor of molecular, cellular Six School of Medicine faculty mem- policy decisions. and developmental biology, professor bers have been elected to the National of dermatology, and Howard Hughes

Academy of Medicine (NAM), the yale honorees: Medical Institute investigator. Iwasaki’s decarlo anthony organization announced Oct. 21 at its • Nita Ahuja, MD, chair and William research focuses on the mechanisms At a ceremony celebrating their selection to the Na- annual meeting. H. Carmalt Professor of Surgery, and of immune defense against viruses at tional Academy of Medicine, (l-r): Nita Ahuja, Rafael Pérez-Escamilla, Akiko Iwasaki, Jorge Galán, and They are among 100 new members chief of surgery at Yale New Haven the mucosal surfaces. Her laboratory Nenad Sestan. Absent from photo: David Schatz. elected by NAM to receive the honor, Hospital. Ahuja is internationally rec- is interested in how innate recognition which recognizes individuals who have ognized for her expertise in gastrointes- of viral infections leads to the genera- metabolic outcomes among Latinos demonstrated outstanding professional tinal cancers, including gastric, rectal, tion of adaptive immunity, and how with type 2 diabetes. achievement and commitment to service and pancreatic cancers and for being a adaptive immunity protects against • David G. Schatz, PhD, chair and in the fields of health and medicine. passionate advocate for mentorship of subsequent viral challenge. She recently Waldemar Von Zedtwitz Professor At a ceremony on Oct. 22 to cel- trainees, staff, and faculty. Ahuja is also showed that a new vaccine strategy of Immunobiology, and professor of ebrate the winners, Robert J. Alpern, a leader in translational epigenetics, can provide preventive and therapeutic molecular biophysics and biochemistry. MD, dean and Ensign Professor of and initiating clinical trials in colorectal protection against viral infections. Schatz has made fundamental contri- Medicine, said those who receive this cancer, pancreatic cancer, and other solid • Rafael Pérez-Escamilla, PhD, pro- butions to our understanding of the honor are the best of the best. “For tumors. In addition, she has developed fessor of public health (social and be- mechanisms that assemble and diver- every one person that gets in, there are biomarkers for early detection of colorec- havioral sciences), director of the Office sify the genes that encode antibodies 10 outstanding people who don’t get tal and pancreatic cancers. of Public Health Practice, and director and T cell receptors. elected that year. So, the competition is • Jorge E. Galán, PhD, chair and of the Global Health Concentration at • Nenad Sestan, MD, PhD, Harvey and incredible, and I think it is a real honor Lucille P. Markey Professor of Mi- the Yale School of Public Health. Pérez- Kate Cushing Professor of Neurosci- when somebody gets elected to the crobial Pathogenesis and professor of Escamilla has launched public health ence, professor of comparative medicine National Academy of Medicine.” cell biology. Galán studies the mo- nutrition and food security research and of genetics and psychiatry, as well as Established originally as the lecular mechanisms of pathogenesis of programs around the world, which executive director of the Genome Edit- Institute of Medicine in 1970 by the Salmonella and Campylobacter, which have been credited with the improve- ing Center. Sestan studies the molecular National Academy of Sciences, NAM cause the majority of food-borne ment of many measurements of health and cellular basis of brain development, addresses important issues in health, illnesses in the world. His lab uses a including breastfeeding outcomes and exploring how neurons acquire distinct science, medicine, and related policy multidisciplinary approach to study iron-deficiency anemia in infants. His identities and form proper synaptic con- and inspires positive actions across the interface between pathogen and health disparities research has focused nections in the cerebral cortex, a part of sectors. NAM works alongside the host. He discovered that such bacteria on the impact of community health the brain that is essential for cognition, National Academy of Sciences and as Salmonella use a needle-like complex workers in improving behavioral and perception, and behavior.

12 www.medicineatyale.org